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1. Summary 
 
Several heritable disorders alter an individual's perception of pain. For instance, patients with 
hereditary sensory and autonomic neuropathies (HSANs) cannot feel pain and do not engage 
appropriate protective behaviours, while pain-related channelopathies can cause both painful 
and painless conditions. Moreover, chronic pain affects millions of people worldwide. 
Elucidation of molecules and signalling pathways that lead to pain sensation is key to 
understanding the mechanisms underlying these pathologies and to the development of 
adequate treatments.  
 
The CRISPR/Cas9 technology is a revolutionising approach in genome editing. This versatile 
system consists of two components: a short guide RNA (gRNA) and a Cas9 nuclease. 
Recognition of a genomic DNA target is mediated through base-pairing with the gRNA, which 
recruits Cas9 to the target site and generates a double-strand break. Subsequently, the repair 
mechanisms of the cell are activated, resulting in deletion or insertion (indel) mutations in the 
DNA sequence. In the present work, two independent models for in vitro and in vivo study of 
pain-related genes were successfully generated using the CRISPR-Cas system for the 
exploration of pain mechanisms.  
 
First, novel putatively pathogenic mutations in the NTRK1 gene were identified in patients with 
hereditary sensory and autonomic neuropathy type IV (HSAN-IV). Functional characterization 
of the mutations was done using CRISPR-Cas-edited PC12 cells in which Ntrk1 was disrupted. 
Western blot analysis of cells overexpressing the mutant proteins revealed altered activation of 
signalling pathways as well as glycosylation defects. Also, neurite outgrowth was impaired in 
Ntrk1-KO PC12 cells expressing the mutant proteins. Localisation studies showed altered 
expression patterns in one of the mutants. Taken together, this cellular system is a valuable tool 
to investigate the pathogenicity of NTRK1 variants and suggests that different perturbations of 
the downstream signalling cascade results in loss of nociceptor function.   
 
Second, a double-knockout (DKO) mouse model disrupting the genetically linked genes 
Scn10A and Scn11a, encoding the ion channels NaV1.8 and NaV1.9, respectively, was 
generated. This mouse model will be used in the near future to address the function of these two 
sodium channels in pain perception. Moreover, DKO-dorsal root ganglion neurones (DRGs) 
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can be used as a cellular model for the functional characterization of NaV1.8 and NaV1.9 
disease-causing protein variants. 
                                                                                                                                        Zusammenfassung 
3 
 
2. Zusammenfassung 
 
Die Schmerzwahrnehmung des Menschen kann durch eine Reihe erblicher Erkrankungen 
beeinflusst werden. Patienten mit einer erblich-bedingten sensibel-autonomen Neuropathie 
(HSAN) empfinden beispielsweise keine Schmerzen und weisen in der Folge schwere 
Verletzungen auf. Von einer Natriumkanalerkrankung betroffene Personen können sowohl 
unter fehlendem Schmerzempfinden als auch unter einem chronischen Schmerzsyndrom und 
einer Neuropathie leiden. Neben diesen erblichen Erkrankungen gibt es eine Vielzahl von 
weiteren Ursachen für chronische Schmerzen, so dass die Entschlüsselung von Molekülen und 
Signalwegen der Schmerzverarbeitung ein wichtiger Schritt auf dem Weg zur Therapie ist.  
 
Die CRISPR/Cas Technologie stellt einen revolutionären Ansatz dar, der auch zum Studium 
von Schmerzerkrankungen genutzt werden kann. Dieses breit einsetzbare System besteht aus 
einer sog. kurzen „guide RNA“ (gRNA) und einer Nuklease, dem Cas9-Protein. Die 
Komponenten des Systems können so adaptiert werden, dass eine gezielte Manipulation 
beliebiger Abschnitte der DNA möglich ist. Durch CRISPR/Cas-induzierte Doppelstrangbrüche 
in der DNA werden so repariert, dass beispielsweise Deletionen oder Insertionen im DNA-
Strang resultieren und Gene stillgelegt werden können. Das CRISPR/Cas-System wurde im 
Rahmen der Arbeit sowohl in-vitro als auch in-vivo erfolgreich zum Studium von Schmerz-
assoziierten Genen und ihren Mechanismen eingesetzt.    
 
Im ersten Abschnitt wurden neue Mutationen im NTRK1-Gen untersucht, die bei Patienten mit 
HSAN Typ 4 identifiziert wurden. NTRK1 gilt als wichtiges Molekül der nozizeptiven 
Funktion. Die funktionelle Analyse der Patientenmutationen erfolgte in PC12-Zellen, in denen 
Ntrk1 zunächst mittels CRISPR/Cas ausgeschaltet wurde. Knockout-Zellen, in denen 
anschließend entweder das humane NTRK1-Wildtypprotein oder eine der Mutanten exprimiert 
wurde, zeigten eine veränderte Signaltransduktion oder Defekte der Glykosylierung des 
NTRK1-Rezeptors. Eine der NTRK1-Mutanten zeigte eine veränderte subzelluläre 
Lokalisation. Zudem war das Neuritenwachstum mutierter Zellen nach NGF-Stimulation 
vermindert. Zusammenfassend erwies sich das Modell als wertvolles System, um humane 
NTRK1-Proteine bezüglich ihrer Fehlfunktion zu untersuchen.   
 
                                                                                                                                        Zusammenfassung 
4 
 
Im zweiten Abschnitt der Arbeit wurde ein Doppel-Knockout Mausmodell mittels CRISPR/Cas 
generiert. Hierbei wurden die beiden im Genom benachbarten und somit gemeinsam vererbten 
Gene Scn10a und Scn11a, die die für Nozizeptoren wichtige Natriumkanäle NaV1.8 und NaV1.9 
kodieren, parallel ausgeschaltet. Die Studie zeigte, dass sich die Spinalganglien dieser Mäuse 
ideal als Expressionssystem für die elektrophysiologische Charakterisierung von NaV1.8 und 
NaV1.9 Mutationen eignen, die bei Patienten mit verändertem Schmerzempfinden eine wichtige 
Rolle spielen. Das Mausmodell wird zukünftig auch die gemeinsame Rolle beider Kanäle in der 
Physiologie des Schmerzempfindens klären können. 
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3. Introduction 
 
3.1   The pain pathway 
Pain is an unpleasant sensory, emotional, and cognitive experience that is usually associated 
with real or potential tissue damage (1). Detection of noxious stimuli alerts us to actual or 
imminent injury and triggers protective responses that are essential for the organism's survival 
and wellbeing.  
 
Nociception is the process by which intense chemical, mechanical or thermal stimuli are 
detected by a subpopulation of specialised peripheral sensory neurones known as nociceptors 
(2). The cell bodies of these neurones reside in the dorsal root ganglia (DRG) and have both a 
central and peripheral axonal branch that innervates the spinal cord and the target organ, 
respectively. There are three main types of nociceptors: Aβ large diameter and Aδ medium 
diameter myelinated fibres, and small diameter unmyelinated C fibres. In contrast to other 
receptors, nociceptors are normally only activated when the intensity of the stimulus reaches the 
noxious threshold. On such occasions, stimuli cause several receptors, ion channels, and other 
cellular machinery to respond and transmit signals to the central nervous system (CNS), where 
the information is processed and perceived as pain (Figure 1) (3).  
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3.2   Hereditary sensory and autonomic neuropathies  
The mechanisms that lead to transmission of peripheral information and the generation of an 
appropriate response are extremely complex. Alterations in the molecular or cellular 
mechanisms involved at any stage of this process can cause serious diseases. Indeed, peripheral 
neuropathies affect many people worldwide and are one of the most common neurological 
disorders (4). 
 
Peripheral neuropathies are diseases of the peripheral nervous system (PNS) in which either the 
axon or the myelin-forming cells surrounding them, the Schwann cells, show dysfunction due to 
metabolic stress, toxicity, infections, or genetic defects (5). Inherited peripheral neuropathies 
can be classified into three different types according to the nerve fibres affected: hereditary 
motor neuropathies, hereditary motor and sensory neuropathies, and hereditary sensory and 
autonomic neuropathies (HSANs) (6). 
 
HSANs are a group of genetically and clinically heterogeneous disorders that include 
phenotypes with pure sensory involvement, others with variable levels of motor involvement 
and minor autonomic disturbance or virtually pure autonomic neuropathies. Loss of pain and 
temperature sensation are the most common symptoms of HSANs and usually lead to chronic 
ulcerations in hands and feet, recurrent unrealized infections, and self-mutilation. Additionally, 
patients with HSAN show axonal injury in sensory neurones and demyelination might also be 
present (6). 
 
HSANs can be subdivided into autosomal dominant forms that typically show juvenile or adult 
onset, and autosomal recessive forms, which usually have an early onset (congenital or during 
childhood). Furthermore, HSAN can be categorised into different subtypes based on age at 
onset, mode of inheritance, and the predominant clinical features (7).  
 
Genetic, electrophysiological, and pharmacological studies during the past decade allowed us a 
better understanding of the molecular and cellular mechanisms underlying HSAN. Indeed, based 
on findings from only a small number of families with the disease, it was possible to identify 
several causal genes and the proteins encoded by them. Some of the altered proteins have clear 
nerve-specific roles, whereas others are ubiquitously expressed proteins involved in different 
mechanisms such as transcription regulation, vesicular transport, sphingolipid metabolism, and 
structural integrity. Even though, to date, only one-third of patients with HSAN have mutations 
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in the already known causative genes. On the other hand, due to the development of new 
sequencing and bioinformatics technologies more disease-associated genes will probably be 
identified in the near future. Consequently, additional insights into the function of the proteins 
encoded by the HSAN-genes responsible for normal development, differentiation, and 
maintenance of the sensory and autonomic neurones are needed in order to develop new 
therapeutic strategies for patients with HSAN (6).  
 
3.2.1   Mutations in NTRK1 cause HSAN type IV 
Hereditary sensory and autonomic neuropathy type four (HSAN-IV), also known as congenital 
insensitivity to pain with anhidrosis (CIPA, OMIM 256800), is a rare autosomal recessive 
disorder caused by a failure of nociceptive and sympathetic neurone development. The complete 
absence of small-diameter unmyelinated fibres and loss of innervation of eccrine sweat glands 
by sympathetic neurones can be observed in skin and nerve biopsies from patients suffering 
from the disease (8, 9). The absence of normal responses to both superficial and deep painful 
injuries along with the inability to sense temperature is characteristic of HSAN-IV patients. 
Accordingly, they are susceptible to multiple accidental injuries such as burns, falls, bone and 
joint fractures, and have a self-mutilating behaviour involving primarily the orofacial region and 
the fingers of both hands and feet (Figure 2A-B). In addition, patients show variable mental 
retardation plus a markedly decreased or absent sweating associated with recurrent episodes of 
fever (10).  
 
Over 50 different missense, nonsense, frameshift, splice site mutations as well as alterations in 
non-coding regions in the neurotrophic tyrosine receptor kinase type 1 (NTRK1, OMIM 191315) 
gene, which encodes the high-affinity nerve growth factor (NGF) receptor 1 (NTRK1), cause 
HSAN-IV in families of various genetic backgrounds (10–15). The NTRK1 gene consists of 17 
exons distributed within a 25-kb region on chromosome 1q21-22 (16, 17). The NTRK1 protein 
is one of three major tyrosine kinases involved in neurotrophin signalling. Upon NGF binding, 
NTRK1 is autophosphorylated resulting in the activation of downstream signalling pathways 
that support neurite outgrowth, survival of sympathetic ganglia and nociceptive sensory 
neurones, and the development and survival of cholinergic neurones of the basal forebrain 
(Figure 2C) (10). Moreover, NTRK1 is an essential modulator of the expression and 
sensitization of several neurotransmitters, receptors, and ion channels expressed by adult 
nociceptors (Figure 3) (18).  
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NTRK1 has an extracellular portion consisting of a leucine rich repeat, flanked on either side by 
a cysteine-rich and two Ig-like domains, a transmembrane and a juxtamembrane domain, a 
tyrosine kinase (TK) domain, and a C-terminal end (19). Mutations in the TK domain are the 
most frequent, though a few have been found in the extracellular domain, responsible for 
binding NGF (20). While frameshift, nonsense, and splice-site mutations typically produce 
aberrant or missing proteins, uncovering the consequences of missense mutations leading to 
single amino acid substitutions requires more detailed functional studies to demonstrate their 
involvement in HSAN-IV and discriminate them from rare polymorphisms.    
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3.2.2   Pain associated disorders: the channelopathies 
Ion channels, located in the membranes of all cells and many cellular organelles, have a pivotal 
role in neuronal function and signalling (Figure 3). Channelopathies are a heterogeneous group 
of disorders resulting from the dysfunction of ion channels that can be acquired or inherited. 
Some channelopathies affect the normal functioning of nociceptors. In some individuals, 
mutations in ion channels can lead to pain insensitivity, whereas in others result in increased 
pain perception. Moreover, single nucleotide polymorphisms in genes encoding ion channels 
might affect an individual’s sensitivity to pain as well as predisposition to, and severity of 
chronic pain after tissue inflammation or neural damage and other acquired pain states (30). 
 
Voltage-gated sodium channels (NaV) are crucial determinants of nociceptor excitability. They 
mediate the influx of sodium ions into the cell in response to local membrane depolarization, 
which results in the generation of an action potential that will eventually transmit the signal to 
the CNS (31). The channels NaV1.7 (32), NaV1.8 (33), and NaV1.9 (34) are all preferentially 
expressed in pain-sensing peripheral neurones; however, they have distinct kinetics and show 
slightly different patterns of expression and sensitivity to the neurotoxin tetrodotoxin (TTX). 
NaV1.7 channels might be relevant to amplify small sub-threshold stimuli and, therefore, act as a 
key determinant of threshold in nociceptor terminals (35). In DRG neurones, NaV1.8 channels 
are crucial for transmission of nociceptive information, as they carry most of the current 
underlying the depolarising phase of the action potential (36, 37), and are essential for repetitive 
firing. NaV1.9 sodium channels can generate persistent currents at near resting membrane 
potential, meaning that these channels are key regulators of membrane excitability (38–40). 
Furthermore, NaV1.8 and NaV1.9 channels can be distinguished from NaV1.7 channels by their 
resistance to TTX (33, 41).  
 
The voltage-gated sodium ion channel NaV1.7 is encoded by the sodium voltage-gated channel 
alpha subunit 9 (SCN9A; OMIM 603415), an 113.5-kb gene comprising 26 exons located on 
chromosome 2q24 expressed selectively in autonomic and sensory neurones (32). The majority 
of DRG neurones expressing NaV1.7 are pain sensing, suggesting this sodium channel has a 
vital role in pain pathogenesis (42). Gain-of-function missense mutations in NaV1.7 are 
responsible for primary erythromelalgia (OMIM 133020) (43–46), paroxysmal extreme pain 
disorder (OMIM 613640) (47–49), and small-fibre neuropathy (OMIM 133020) (50). On the 
other hand, loss-of-function mutations lead to congenital insensitivity to pain and HSAN 
(OMIM 243000) (51) type IID (OMIM 243000) (52), two conditions in which affected 
individuals are unable to feel physical pain. 
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The voltage-gated sodium channels NaV1.8 and NaV1.9 are encoded by the sodium voltage-
gated channel alpha subunit 10 (SCN10A; OMIM 604427) and the sodium voltage-gated 
channel alpha subunit 11 (SCN11A; OMIM 604385) respectively. Both genes are located on 
chromosome 3p22.2, one after the other, meaning they are linked genes and, thus, likely to be 
inherited together. NaV1.8 is expressed in myelinated and unmyelinated axons of DRG 
neurones, in contrast to NaV1.9 that is only expressed in myelinated fibres (53). Painful and 
painless neuropathies have been recently associated with these genes. Gain-of-function missense 
mutations in SCN10A result in small fibre neuropathy (OMIM 615551) (54–56), while in 
SCN11A cause congenital insensitivity to pain (57–59), familial episodic pain syndrome type III 
(60–62), painful small fibre neuropathy (63, 64), and cold-aggravated peripheral pain (65). 
3.3   Peripheral neuropathies: a persisting challenging problem 
Solely in the United States, an estimated 15 to 20 million people over age 40 suffer from some 
type of peripheral neuropathy (4). Diagnosis of peripheral neuropathies is often made based on 
the patient medical history and prevailing symptoms. Physical examinations such as nerve 
biopsies can be useful to evaluate the presence of nerve fibre damage, while nerve conduction 
studies might be crucial to confirm severe impairment of sensory/motor nerve conduction 
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velocities as well as absent or altered sensory/motor nerve action potentials (5). Additionally, 
performing different biochemical tests along with DNA sequencing, which allows identification 
of potential gene mutations, is crucial for the correct assessment of the disease.   
 
However, management of pain and dysesthesia in these disorders is a challenging task. Though 
various symptomatic therapies exist which address pain in peripheral neuropathies, these are 
mostly inefficient. Moreover, to date, there are almost no effective treatments to prevent axonal 
degeneration or Schwann cell dysfunction characteristic of peripheral neuropathies (5).  
 
Establishing cellular or mouse models to study hereditary neuropathies prove to be crucial for 
understanding the genetic and molecular basis of pain. Indeed, mutations in both NTRK1 and 
the voltage-gated sodium channel genes SCN10A and SCN11A cause painful and painless 
neuropathies and are potential analgesic targets (19, 66). Many mutations identified in patients 
with these conditions are single-base substitutions distributed throughout the coding sequence 
(10, 11, 67). Investigating the functional consequences of these mutations will not only enable a 
deeper understanding of protein function but also shed light on the underlying disease 
mechanisms causing the variable phenotypes found in patients. Moreover, gaining an in-depth 
insight into these rare heritable pain disorders may be translated into therapy.  
 
3.4    Genome engineering and programmable nucleases 
Generally speaking, genome engineering refers to the process of generating specific 
modifications to the genome, its contexts, or its outputs. Technologies that can delete, insert, 
and modify DNA (deoxyribonucleic acid) sequences of cells or organisms allow researchers to 
elucidate the function of disease-related genes and regulatory elements. Moreover, multiple 
editing could further enable establishing gene or protein interaction networks that could help to 
understand complex disease mechanisms. Thus, our ability to manipulate the genome easily and 
efficiently, particularly in mammalian cells, holds tremendous potential to revolutionise basic 
research and medicine (68).  
 
Eukaryotic genomes contain millions of DNA bases, and their manipulation is challenging. The 
development of gene targeting by homologous recombination (HR), which allows the 
integration of exogenous designed DNA flanked by sequences homologous to the donor site 
(69), was a major breakthrough. Thanks to this technique, researchers were able to generate 
knockin and knockout animal models via manipulation of stem cells, which has led to huge 
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progress in many areas of biological research. Still, even though HR-mediated gene targeting 
produces extremely precise modifications, the recombination frequency is very low (69), and the 
procedure is costly and time-consuming (68).  
 
In recent years, the development of programmable nuclease-based genome editing technologies 
has enabled researchers to overcome such challenges, facilitating specific and efficient alteration 
of several eukaryotic and mammalian genomes (68). These enzymes can generate targeted DNA 
double-strand-breaks (DSBs) that can stimulate editing through HR-mediated recombination 
events (70, 71) as well as induce insertions or deletions (indels) via the error-prone non-
homologous end-joining (NHEJ) repair pathway (72). 
 
Of the various genome editing nucleases that have been developed up to date, the most rapidly 
emerging are the RNA (ribonucleic acid)-guided DNA endonucleases from the bacterial 
adaptive immune system CRISPR (clustered regularly interspaced short palindromic repeats), 
known as Cas9 (CRISPR-associated protein 9) (73, 74) which can be easily targeted to 
practically any genomic region of choice by a short RNA guide (68).  
 
3.4.1   CRISPR/Cas, the adaptive immune system of bacteria and archaea 
All organisms need to defend themselves against infection by potentially harmful invaders, 
collectively known as pathogens. The immune system is usually divided into innate and 
adaptive, though these are not mutually exclusive. In multicellular organisms, innate (non-
specific) immune responses act as a first line of defence and include protective barriers, toxic 
molecules, and phagocytic cells that ingest and destroy invading microorganisms (75). Bacteria 
and archaea possess several innate immunity-like systems such as abortive infection, toxin-
antitoxins, receptor mutation, and restriction-modification (76). Unlike innate responses, 
adaptive responses have three essential characteristics: specificity, diversity, and memory. 
Specificity is crucial to identify exogenous structures and organisms that need to be attacked and 
distinguished from those that have to be tolerated. Diversity in the immune response is required 
to defend the host from a large variety of pathogens and malignant elements. Lastly, a memory 
of past infections allows a more efficient response to recurrent infections and enables the host to 
react rapidly upon re-exposure (59). Adaptive responses were thought to be exclusively present 
in higher eukaryotes until the recent discovery of the CRISPR-Cas system, which provides 
specific and acquired immunisation against invasive mobile genetic elements (MGEs) such as 
plasmids and viruses in Prokaryotes (77–81). 
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In response to viral and plasmid encounters, bacteria and archaea incorporate small fragments of 
foreign nucleic acid into the host chromosome at the leader end of a repetitive element, known 
as the CRISPR array (77, 82). These provide the ‘immune memory’ and consist of a series of 
direct repeats of approximately 20 to 50 base pairs separated by unique spacer sequences of a 
comparable length, which derive from the invading MGEs (83). CRISPR arrays are flanked by a 
large number of highly genetically and functionally diverse cas (CRISPR-associated) genes, 
comprising the CRISPR locus (79, 84). The Cas proteins provide the machinery for defence, and 
most of them carry functional domains that interact with nucleic acids, for example, DNA 
binding, RNA binding, helicase, and nuclease motifs (79, 85–89). CRISPR arrays are 
transcribed into a long primary transcript (pre-crRNA) that is processed into a library of short 
CRISPR-derived RNAs (crRNAs) complementary to a previously encountered MGE sequence 
(90–95). Each crRNA is wrapped into a large complex, known as the crRNA-guided 
surveillance complex, which patrols the intracellular environment and mediates detection and 
specific destruction of the foreign MGEs (81, 82, 90, 96–99). 
 
CRISPR-Cas systems are highly diverse among species and can be divided into two main 
classes, six major types (type I-VI), and multiple subtypes based on the genes encoding the 
surveillance complex and its architecture (100, 101). Type I and III CRISPR-Cas systems, as 
well as the putative type IV, are classified as class 1 systems and possess multisubunit 
surveillance complexes: the CRISPR-associated complex for antiviral defence (Cascade) in type 
I and Csm or Cmr complex in type III. Class 2 systems, in which all functions of the 
surveillance complex are carried out by a single protein, include type II (Cas9 protein), the 
recently established type V (Cpf1, C2c1 or C2c3 proteins), and type VI (C2c2 protein) (100, 
101).  
 
CRISPR-Cas systems work in three steps: acquisition (spacer incorporation), expression 
(crRNA processing and target binding) and interference (target cleavage) (88). Moreover, recent 
studies suggest that CRISPR–Cas systems can also be used for non-defence roles, such as the 
regulation of collective behaviour and pathogenicity (102–104).  
 
Acquisition requires the endonucleases Cas1 and Cas2, which obtain new spacer sequences 
(protospacers) and integrate it to the CRISPR array (105). The CRISPR-repeat sequence is 
duplicated after each spacer integration, hence maintaining the repeat-spacer-repeat structure 
(106). The cas1 gene can be found in most CRISPR-cas loci while the protein sequence is the 
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best conserved among all Cas proteins (88, 100, 107). Cas1 is an integrase that cleaves at 
specific sites within the repeats of the CRISPR array facilitating the incorporation of spacers. 
Cas2 substantially increases integration activity, but its role is less well understood (105, 108). 
Furthermore, in type II systems Cas9 is also involved in acquisition and might provide sequence 
specificity (109, 110).  
  
Protospacers are not randomly chosen, and in many CRISPR-Cas systems, selection requires 
recognition of a short protospacer adjacent motif (PAM) in the target DNA (111–113). PAM 
sequences are only a few nucleotides long, and the exact sequence varies depending on the 
CRISPR system type and the bacterial species. In addition, the PAM is an essential component 
that facilitates self versus non-self discrimination to avoid the CRISPR locus itself from being 
targeted (114). 
 
During expression, the cas genes and the CRISPR array are transcribed. The pre-crRNA is 
transcribed from the leader sequence (81) and further processed into crRNAs containing the 
MGE-derived spacer sequence and portions of the repeats (90–95). Generation of crRNAs 
differs between the two classes of CRISPR-systems. In class 1 systems, crRNA production 
usually involves a Cas6 endoribonuclease (95) whereas in the class 2 systems the scenario is 
more diverse. Type II systems require Cas9, RNase III and a non-coding RNA, named 
transactivating crRNA (tracrRNA), for pre-crRNA processing (91). However, in Neisseria 
meningitides (type II-C system) transcription is initiated within each spacer, driven by promoter 
elements embedded within each repeat and, unexpectedly, pre-crRNA processing is not required 
(115). In type V systems, C2c1 also needs a tracrRNA (101) while Cpf1 produces crRNA 
independently of a tracrRNA (116). C2c2 generates mature crRNA without a tracrRNA in type 
VI systems (101).  
 
The crRNAs form a ribonucleoprotein complex with the Cas proteins, and in type II (91) and 
some type V systems (101) also with the tracrRNA. During interference, these surveillance 
complexes recognise and degrade the MGEs. In type I systems, recognition of complementary 
DNA by Cascade results in the recruitment of the Cas3 helicase-nuclease, which degrades the 
invasive DNA (117, 118). Type III systems target DNA and RNA in a transcription-dependent 
manner. Hence, these systems only interfere with transcriptionally active phages (119). Finally, 
type II and type V interference results in DNA degradation, while type VI degrades single-
stranded RNA (ssRNA) (101, 120). Remarkably, the large (~950–1,400 amino acids) 
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multidomain Cas9 protein is necessary for all three steps of CRISPR-based immunity in type II 
systems and, therefore, concentrating much of the CRISPR-Cas system’s function in a single 
protein (79, 100).  
 
ʹ
ʹ
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3.4.2   Type II systems and their use in genome engineering 
The development of the Cas9 nuclease for genome editing is the result of more than a decade of 
basic research into deciphering the biological function of the CRISPR-Cas system, which is 
present in more than 40% of sequenced bacteria and 90% of archaea (122). Given that the 
CRISPR arrays and cas genes appeared to be well conserved (123), interest in such microbial 
repeat elements began to increase, though it was only in 2007 when the first experimental 
evidence of the role of CRISPR systems in adaptive immunity was uncovered (77).  
 
By 2010, researchers had a clear overview of the building blocks and mechanisms of CRISPR 
systems, and several groups began to take advantage of this natural system for several 
biotechnological applications including the production of phage-resistant dairy cultures (124). 
Around the same time, it was reported that in type II CRISPR systems DNA cleavage solely 
requires Cas 9 (82) and this protein, together with RNase III and a tracrRNA-crRNA hybrid, 
processes the pre-crRNA into mature crRNAs, which then guide Cas9 to its DNA target (91). 
Therefore, theoretically, only three components (Cas9, mature crRNA, and tracrRNA) seemed 
to be essential for reconstituting the type II CRISPR system in mammalian cells and, due to its 
simplicity, could be used as an RNA-programmable DNA endonuclease for genome editing.  
 
In 2012, it was demonstrated that crRNAs could guide Streptococcus thermophilus or 
Streptococcus pyogenes purified Cas9 to cleave target DNA in vitro (125, 126). One year later 
two groups simultaneously achieved to engineer type II CRISPR systems from S. thermophilus 
(73) and S. pyogenes (73, 74) and successfully edited mammalian-cell genomes. Both a crRNA-
tracrRNA hybrid and a single guide RNA (sgRNA), in which the crRNA 3’and tracrRNA 5’ 
ends are connected by a tetraloop, can direct Cas9 cleavage to a particular sequence of the 
cellular genome to promote NHEJ or homology-direct repair (HDR)-mediated genome editing 
(73, 74, 125). Since these pioneering studies, Cas9, especially S. pyogenes Cas9 (SpCas9), has 
been used by numerous research laboratories for genome editing in a wide range of 
experimental model systems (127).  
 
All Cas9 proteins share a similar structure composed of six domains. The RuvC and HNH 
nuclease domains are responsible for DNA cleavage, while REC I binds the guide RNA. REC II 
forms a bridge helix crucial for initiating cleavage, whereas the PAM interacting C-terminal 
region confers PAM specificity and activates the nuclease domains (128–130). The guide RNA 
functions as a scaffold around which Cas9 can fold and organise its various domains (128). 
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To direct Cas9 to a particular DNA sequence, SpCas9 requires twenty nucleotides (nt) at the 5′ 
end of the crRNA (or sgRNA) directly matching the target site along with a 5′-NGG PAM 
sequence, where N can be any nucleotide, immediately downstream of the target sequence 
(125). Type II systems from other bacterial species that recognise other PAM sequences and 
differ in the tracrRNA and crRNA sequences have also been used for genome editing, such as 
Neisseria meningitides Cas9 (NmeCas9). While both Cas9 proteins produce DSBs three base 
pairs (bp) upstream of the PAM sequence, in contrast to SpCas9, NmeCas9 requires a twenty-
four nucleotide target guide sequence followed by a 5’-NNNGATT PAM to cleave DNA 
(Figure 5) (131, 132). In this thesis, I will exploit these nucleases for generating mouse and 
cellular models to study pain-related-gene mutations.  
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3.5   Objectives  
Studying gene function in a biological context proves to be essential to understanding the 
genetic and molecular basis of pain and might eventually lead to improved diagnosis and novel 
therapeutic strategies for patients with peripheral neuropathies. Therefore, the main aim of this 
thesis was the generation of models that would enable a faster characterization of unreported 
putative disease-causing mutations in genes involved in pain perception using the recently 
developed genome engineering method CRISPR-Cas, in particular: 
 
 Generation of a cellular knockout model for functional characterization of missense 
mutations in the NTRK1 gene.  
 
 Validation of the model by functional characterization of recently identified NTRK1 
mutations of unclear clinical significance.  
 
 Comparing different CRISPR/Cas-based approaches to disrupt genetically linked genes in 
mice simultaneously, and generating Scn10a and Scn11a double-knockout mice.  
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4. Materials and Methods  
 
4.1   Materials 
 
4.1.1   Bacteria 
For amplification of DNA plasmids, the bacterial strain Escherichia coli XL-1-Blue was used.  
 
4.1.2   Cell lines 
PC12, HEK293T and HeLa cells were used. PC12 is a rat cell line that was derived from a 
pheochromocytoma of the adrenal medulla (133). PC12 cells cease to proliferate and undergo 
terminal differentiation into a neuronal phenotype when treated with nerve growth factor (NGF) 
(134). HEK293T is a highly transfectable cell line derivative of human embryonic kidney 293 
cells and contains the SV40 T-antigen (135), while HeLa cells derived from an epidermoid 
carcinoma of the human cervix (136). Cell lines were a gift from Prof. Dr. rer. nat. Aria 
Baniahmad. 
 
4.1.3 Antibodies 
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4.1.4 DNA Plasmids 
 
 
 
 
                                                                                                                                   Materials and Methods 
22 
 
4.1.5 Kits 
 
Amaxa SF cell line 4D-Nucleofector X Kit S and L Lonza 
BigDye® Terminator v1.1 Cycle Sequencing Kit Applied Biosystems 
Clarity™ Western ECL Substrate  Bio-RAD 
DNA Clean & Concentrator™ Zymoclean 
Gel DNA Recovery Kit - Uncapped columns  Zymoclean  
MEGAclear™ Transcription Clean -Up Kit Thermo Scientific 
MEGAshortscript™ T7 Transcription Kit  Thermo Scientific 
NucleoBond® Xtra Midi / Maxi Macherey-Nagel 
Pierce™ BCA Protein Assay Kit  Thermo Scientific 
Plasmid Miniprep Kit I, peqGOLD VWR Peqlab 
Quick-RNA
™
MiniPrep Zymoclean 
TOPO® TA Cloning® Kit with pCR®2.1 TOPO® Invitrogen 
 
4.1.6 Chemicals and Reagents 
 
1-kb Plus DNA ladder Life Technologies 
5× Herculase II Reaction Buffer Aligent Technologies 
50 mM MgCl2  Thermo Scientific 
5X First-Strand Buffer Thermo Scientific 
5X Phusion HF Buffer Thermo Scientific 
Acrylamide/bisacrylamide mixture, Rotiphorese® Gel 40 Roth 
Bovine serum albumin (BSA), pH 7.0 PAA 
BsmbI Thermo Scientific 
CoralLoad PCR Buffer QIAGEN 
CoralLoad PCR Buffer, 10X QIAGEN 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 
DMEM, high glucose, GlutaMAX™ Supplement, pyruvate 
 
Thermo Scientific 
DPBS, no calcium, no magnesium Thermo Scientific 
DTT Thermo Scientific 
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EcoRV Thermo Scientific 
Exonuclease I  Thermo Scientific 
FastAP™ Thermosensitive Alkaline Phosphatase or Shrimp Thermo Scientific 
FastDigest BbsI (BpiI) Thermo Scientific 
FastDigest buffer, 10X Thermo Scientific 
Fetal bovine serum (FBS) Biowest 
Fluoromount-G Southern Biotech 
GlutaMAX™ Supplement Gibco 
Herculase II Fusion DNA Polymerase Aligent Technologies 
Herculase II 5X reaction buffer Agilent Technologies 
Hi-Di™ Formamide Thermo Scientific 
Hoechst 33258 Invitrogen 
Horse serum (HS) Sigma 
HotStarTaq Plus DNA Polymerase QIAGEN 
Krebs-Ringer Bicarbonate Buffer  Sigma 
Lipofectamine® 2000 Reagent Invitrogen 
Laminin (from mouse Engelbreth-Holm-Swarm sarcoma) Roche 
M16 medium Sigma 
M2 medium  Sigma 
MluI Thermo Scientific 
Nerve Growth Factor 2.5S subunit (NGF) Invitrogen 
Opti-MEM I reduced-serum medium Gibco 
PageRuler Thermo Scientific 
PageRuler Plus Prestained Protein Ladder Thermo Scientific 
Penicillin-Streptomycin (P/S), 5,000 U/mL Gibco 
Phusion High-Fidelity DNA Polymerase Thermo Scientific 
Poly-L-lysine hydrobromide (PLL) Sigma 
PrecisionX™ Cas9 SmartNuclease mRNA (Eukaryotic version) System Biosciences 
Protease Inhibitor Cocktail Tablets Roche 
PscI Thermo Scientific 
PVDF membrane (0.45 μm) Amersham Hybond™ 
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QIAGEN PCR Buffer, 10X QIAGEN 
QuickExtract DNA extraction solution Epicentre 
Random Primers Thermo Scientific 
RNaseOUT™ Thermo Scientific 
Roswell Park Memorial Institute 1640 Medium Gibco 
SuperScript ® III Reverse Transcriptase Thermo Scientific 
SmaI Thermo Scientific 
T4 DNA Ligase Thermo Scientific 
T4 DNA Ligase Buffer (10X) Thermo Scientific 
TRIzol® reagent Thermo Scientific 
UltraPure DNase/RNase-free distilled water Gibco 
SsoAdvanced™ Universal SYBR® Green Supermix Bio-Rad 
XcmI Thermo Scientific 
  
4.2. Methods  
 
4.2.1   General molecular biology methods 
 
4.2.1.1   Preparation of competent bacteria 
The prerequisite for bacteria to undergo transformation is their ability to take up free, 
extracellular genetic material. Such bacteria are termed competent cells and are needed for the 
amplification of plasmid DNA. For the preparation of competent bacteria, a preculture of E. 
coli XL1 Blue was grown overnight at 37°C in 2 ml LB broth medium (4 mM MgSO4, 10 mM 
KCl, 3 µg/ml tetracycline, pH 7.0). The following morning, 1 ml of the preculture was 
inoculated with 500 ml broth medium and grown at 37°C in a shaking incubator until an optical 
density at 600 nm (OD600) of 0.3-0.6 was reached. Bacteria were cooled on ice and then 
centrifuged at 3000 rpm for 5 minutes at 4°C. The pellet was resuspended in 150 ml ice-cold 
TFB1 buffer (15% glycerol, 10 mM CaCl2, 30 mM potassium acetate, 100 mM RbCl, 50 mM 
MnCl2, pH 5.8) and incubated on ice for 60 minutes. Afterwards, the bacterial suspension was 
centrifuged again at 3000 rpm for 5 minutes at 4°C, and the pellet was resuspended in ice-cold 
TFB2 buffer (15% glycerol, 10 mM MOPS, 75 mM CaCl2, 10 mM RbCl). The competent cells 
were quickly aliquoted, frozen in liquid nitrogen, and stored at -80°C.  
 
                                                                                                                                   Materials and Methods 
25 
 
4.2.1.2   Bacterial transformation 
An aliquot of competent bacteria was thawed on ice for 30 min. Transformation was performed 
by adding 1 μg of plasmid DNA to 50 μl of competent E.coli XL-1 Blue bacteria followed by 
incubation on ice for 5 min. For the heat shock, tubes were placed into a 42°C water bath for 60 
seconds and placed back on ice for 2 min. Afterwards, 250 μl of SOC medium (0.5% yeast 
extract, 2% tryptone, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM 
Glucose, pH 7.0) were added and bacteria were grown at 37°C for 1 hr in a shaking incubator at 
300 rpm. Then, cells were centrifuged at 3000 rpm for 10 min. 200 ul of supernatant fraction 
were removed, and cells were resuspended and plated on LB agar (1% NaCl, 1% tryptone, 
0.5% yeast extract, 1.5% agar, pH 7.0) containing antibiotics according to the resistance marker 
encoded by the plasmid DNA to be amplified. LB agar plates were incubated at 37°C overnight.  
 
4.2.1.3   Midi preparation of plasmid DNA 
Applications like mammalian cell transfection require large amounts of highly pure DNA. To 
achieve high-quality DNA, a single bacterial colony was inoculated in 200 ml LB medium (1% 
NaCl, 1% tryptone, 0.5% yeast extract, pH 7.0) supplemented with the respective antibiotic. 
Bacteria were grown at 37°C in a shaking incubator overnight. Purification of plasmid DNA 
was done using the NucleoBond® Xtra Midi/Maxi Kit following the manufacturer’s 
instructions. Following alkaline lysis of bacteria, the plasmid DNA was purified on an anion-
exchange column. Eluted plasmid DNA was precipitated with isopropanol, washed with 70% 
ethanol, dried, and resolved in an appropriate volume of TE buffer (10 mM Tris-HCl pH 7.5, 1 
mM EDTA). DNA concentration and purity were assessed by absorbance at 260 nm and 280 
nm (NanoDrop 2000©, Thermo Scientific). 
 
4.2.1.4   Minipreparation of plasmid DNA  
A single bacterial colony was inoculated in 2 ml of LB medium supplemented with the 
respective antibiotic. Bacteria were grown at 37°C in a shaking incubator overnight. 
Purification of plasmid DNA was done using the peqGOLD Plasmid Miniprep Kit I following 
the manufacturer’s instructions. In brief, after alkaline lysis of bacteria, the plasmid DNA was 
purified on an anion-exchange column and further eluted in 50 µl of distilled water. DNA 
concentration and purity were assessed by absorbance at 260 nm and 280 nm.  
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4.2.1.5   Agarose gel electrophoresis 
Separation of DNA fragments from PCR reactions or restriction digests was achieved by 
horizontal gel electrophoresis in agarose gel chambers. Agarose gel concentration was 1-2 % 
depending on the purpose and size of the DNA fragments to be separated. Agarose was boiled 
in 1X TAE buffer (40 mM Tris-acetate, 1 mM EDTA). Before casting the gel, 0.5 µg/ml 
ethidium bromide was added. To assist gel loading and monitor DNA separation, DNA samples 
were mixed with 5X DNA loading buffer (30% glycerine, 0.25% bromophenol blue, and 0.25% 
xylene cyanol). DNA fragments were separated by applying a constant voltage between 30-150 
V depending on the desired separation time. After separation, DNA was visualised under UV 
light. 
 
4.2.1.6   Non-denaturating polyacrylamide gel electrophoresis (PAGE) 
In the absence of denaturants, double-stranded DNA (dsDNA) retains its double helical 
structure and can be separated (fragments of up to 1000 bp) on non-denaturating 
polyacrylamide gels (native PAGE). In this type of gel, the mobility of dsDNA is affected not 
only by its size but also by its sequence composition, as certain sequences may cause bending 
of the helical structure leading to slow migration of the fragment hampering the determination 
of molecular weight.  
 
This principle can be used for the identification of genome-modified mice or cells carrying 
CRISPR/Cas9-mediated indel mutations with high sensitivity and accuracy. After DNA 
isolation from mouse tails or cells, the genomic region spanning the sgRNA binding site was 
amplified by PCR using CoralLoad PCR Buffer. This buffer can be used to directly load the 
PCR reaction onto a gel as it contains two marker dyes - an orange dye and a red dye - that 
facilitate estimation of DNA migration distance. PCR fragments from genetically modified 
animals or cells, which contain a mixture of indel mutations and wild-type alleles, form both 
heteroduplex and homoduplex DNA (Figure 6A). Due to the existence of an open angle 
between matched and mismatched DNA strands caused by indel mutations, heteroduplex DNA 
migrates at a significantly slower pace than homoduplex DNA during native PAGE. Therefore, 
one can assess the number and even the type of indel mutations simply based on their 
heteroduplex mobility pattern. Hence, Non-denaturating gels are a useful tool to screen mice or 
cells harbouring indel mutations (Figure 6B) as it provides additional information to standard 
denaturating gels (137). 
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Washed plates were assembled with a 0.75 mm spacer for casting acrylamide gels. The PCR 
products were resolved by electrophoresis in a gel containing 5% acrylamide-bisacrylamide, 
10X TBE buffer (1 M Tris base, 1 M Boric Acid, 0.02 M EDTA), Ammonium Persulfate and 
TMED. After 1 hr electrophoresis at 100 V in 1X TBE buffer run in a Mini-PROTEAN®3 
System (Biorad), polyacrylamide gels were immersed in 0.5% ethidium bromide solution for 10 
min before visualisation under UV light. 
 
As it is not possible to identify homozygous indel mutations unless PCR products from wild-
type and mutant alleles are mixed, following the standard genotyping analysis by loading PCR 
samples directly onto the 5% gels, 10 µl of each mutant and wild-type PCR products were 
mixed. A drop of paraffin oil was added on top of the solution and placed in boiling water for 
denaturation. The PCR products were allowed to reanneal by leaving the solution in the water 
and let it cool at room temperature (RT) for at least 3 hr before loading onto the gel. 
 
4.2.1.7   Digestion of plasmids and PCR Fragments 
All DNA digestions were carried out using a final volume of 30 µl. In general, 3 µg of plasmid 
DNA or 5 µl of purified PCR product were mixed with 1 µl of enzyme plus 3 µl of the 
corresponding buffer. The digestion mixture was incubated for 3 hr or overnight at 37°C or 
30°C, depending on the enzyme. After enzyme inactivation, the DNA was gel-purified.  
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4.2.1.8   DNA purification from agarose gels 
Under UV light, DNA bands were excised quickly from the agarose gel using a sharp scalpel 
and placed into a 1.5 ml tube. DNA was purified using the Gel DNA Recovery Kit. Following 
addition of 500 µl of agarose dissolving buffer to the agarose gel slice and incubation at 56°C 
for 10 min, the melted agarose solution was transferred to a Zymo-Spin™ Column in a 
collection tube and centrifuged for 60 seconds. The flow-through was discarded, and 200 µl of 
DNA Wash Buffer were added to the column and centrifuged for 30 seconds two times. An 
appropriate volume of distilled water ranging from 5 to 20 µl was directly added to the column 
matrix and centrifuged for 2 min at full speed to elute DNA. 
 
4.2.1.9   DNA ligation 
To clone plasmid constructs, insert, and vector fragments with compatible ends were ligated. A 
typical ligation mixture was performed in a total volume of 20 µl containing 1 µl of T4 DNA 
Ligase, 2 µl of T4 DNA Ligase Buffer, 1 µl of vector DNA, and different amounts of insert 
ranging from 1 to 6 µl. The ligation mixture was incubated overnight at 4°C, and 5 µl of the 
ligation reaction were used to transform chemo-competent bacteria.  
 
4.2.1.10   Colony PCR 
To sequence independent alleles, Taq polymerase-amplified PCR products were cloned into 
pCR®2.1 TOPO® vector using the TOPO® TA Cloning® Kit. The plasmid is supplied 
linearized with 3´-deoxythymidine (T) overhangs and Topoisomerase I covalently bound to the 
vector. Taq polymerases have a nontemplate-dependent terminal transferase activity that adds a 
single deoxyadenosine (A) to the 3´ ends of PCR products. This allows PCR inserts to ligate 
efficiently with the vector. A reaction mix containing 1 µl of Salt Solution, 1 µl of TOPO 
vector, 4 µl of PCR product and 4 µl of water was prepared. Following incubation at RT ( 22–
23°C) for 10 min, 5 µl of the reaction mixture were used to transform competent bacteria. The 
following day, DNA was extracted from 10 colonies using the QuickExtract™ DNA Extraction 
Solution, which can be used to rapidly and efficiently extract PCR-ready genomic DNA. Each 
bacterial colony was resuspended in 5 µl of this solution and incubated for 6 min at 65˚C 
followed by 2 min at 98˚C. The resulting DNA was used as a template for PCR amplification of 
inserts using the M13 forward (fwr; 5´-GTAAAACGACGGCCAG-3´) and reverse (rev; 5´-
CAGGAAACAGCTATGAC-3´) primers provided with the kit. 2.5 μl DNA were used in a 
single PCR mix containing 0,1 µl of HotStarTaq Plus DNA Polymerase, 0.5 µl dNTPs, 2 µl of 
10X QIAGEN PCR Buffer, and 1 µl of each primer. The amplification was carried out in a 
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PCR thermal cycler using the following program: 5 min at 95˚C, 40 cycles of 20s at 95˚C, 20s 
at 50˚C, 40s at 72˚C followed by a final 10 min extension step at 72˚C. The amplified DNA 
fragments were mixed with 5 µl of 5x DNA loading buffer and separated on a 2% agarose gel. 
Only the colonies containing an insert were sequenced. 
 
4.2.1.11   DNA Sequencing  
Sequencing of plasmids and PCR products was carried out using the BigDye Terminator v1.1 
Cycle Sequencing Kit. Briefly, 3 μl of PCR product was cleaned in a reaction volume of 10 µl 
containing 1 μl of ExoSAP (1 Exonuclease I: 2 FastAP™ Thermosensitive Alkaline 
Phosphatase or Shrimp Alkaline Phosphatase) that removes unincorporated primers and 
degrades unincorporated nucleotides. The mixture was incubated at 37˚C for 15 min followed 
by 15 min at 80˚C. Sequencing PCR was performed in a reaction volume of 10 μl containing 5 
μl of purified PCR product or 1 μl of plasmid, 1 μl Ready Reaction Mix, 2 μl BigDye 
Terminator v1.1 Sequencing Buffer and 0.5 μl of a 10 pmol/μl solution of the corresponding 
primer. The amplification was carried out in a PCR thermal cycler using the following program: 
15s at 96˚C, 27 cycles of 15s at 96˚C, 15s at 55˚C, 4 min at 60˚C. Purification of this PCR 
product was done by adding 2 μl of sodium acetate (3 M, pH 5.2) and 50μl of 100% ethanol, 
incubated at RT for 15 min and then centrifuged for 30 min at 14000 rpm. The pellet was 
washed two times by adding 50 μl of 70% ethanol and centrifugation for at 14000 rpm. The 
supernatant fraction was removed, and the sample was dried for 15 min at RT, and 10 μl of Hi-
Di™ Formamide were later added to each sample. Automated electrophoreses were performed 
on a capillary electrophoretic ABI 3130 genetic analyser (Applied Biosystems). Sequences 
were aligned and analysed with Benchling (www.benchling.com) or SnapGene® software 
(from GSL Biotech; available at www.snapgene.com).  
 
4.2.1.12   Isolation of RNA from cells 
For the isolation of RNA from cells, the Quick-RNA
™
 MiniPrep Kit was used following the 
manufacturer’s instructions. Briefly, cells were plated in 10 cm dishes and grown at 37 ˚C. 
When confluent, cells were washed two times with DPBS and lysed by adding 600 µl RNA 
Lysis Buffer directly to the monolayer. Afterwards, the RNA was purified on an anion-
exchange column and further eluted in 30 µl of UltraPure DNase/RNase-free distilled water. 
RNA concentration and purity were assessed by absorbance at 260 nm and 280 nm.  
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4.2.1.13   Isolation of RNA from tissue samples 
Mice were sacrificed via cervical dislocation and tissue was collected, frozen in liquid nitrogen, 
and stored at -80°C. The following day, the tissue was ground with a mortar and pestle into 
powder using liquid nitrogen and transferred to a 50 ml falcon. 1 ml TRIzol® reagent was 
added per 100 mg tissue. Samples were thoroughly vortexed and incubated for 5 min at RT and 
centrifuged for 5 minutes at 4,000 g at 20°C. The supernatant fraction was transferred to a new 
tube. 200 µl of chloroform per 1 ml TRIzol® was added. Samples were shaken by hand for 30 
seconds followed by 2 min incubation at RT and subsequently centrifuged at 14,000 rpm at 4°C 
for 15 minutes. The aqueous phase (upper) was transferred to a new tube, and the RNA was 
precipitated by adding 1 volume of isopropanol followed by 10 minutes incubation at RT and 
centrifuged at 13000 rpm at 4°C for 10 minutes. The resulting RNA pellet was washed with 
75% ethanol, dried, carefully solved in UltraPure DNase/RNase-free distilled water, and stored 
at-80°C until further use. 
 
4.2.1.14   Reverse transcription  
To analyse the expression of the different genes, RNA was extracted from cells or tissue, and 
complementary DNA (cDNA) was generated using SuperScript ® III Reverse Transcriptase. 
For each reaction, 5 μg of total RNA were mixed with 1 µl Random Primers, 1 µl 10 mM dNTP 
mix completed to a final volume of 13 µl with UltraPure DNase/RNase-free distilled water. The 
reaction was incubated at 65°C for 5 min, then placed on ice for at least 1 min. Afterwards, 4 µl 
of 5X First-Strand Buffer, 1 µl 0.1 M DTT, 1 µl RNaseOUT™, and 1 µl SuperScript® III were 
added. The reaction mixture was incubated for 5 min at 25°C followed by 60 min at 50°C, and 
70°C for 15 min. cDNA synthesis reactions were stored at −20°C. 
 
4.2.2   Generation of Ntrk1-KO PC12 cells and functional characterization of NTRK1 
mutants  
 
4.2.2.1   Maintenance of PC12 cells 
Rat PC12 cells were grown at 37°C (5 % CO2) in supplemented RPMI medium (Roswell Park 
Memorial Institute 1640, containing high glucose, 1 % GlutaMAX™ Supplement, 1 % 
pyruvate, plus 10% FBS, 1 % P/S ). Cells were seeded onto T-75 cm
2
 flasks coated with 0.1 
mg/ml poly-D-lysine hydrobromide and split every 3 to 4 days at a ratio of about 1:2. For 
splitting, cell culture medium was removed, and the cell layer was gently rinsed with 
phosphate-buffered saline (PBS) to remove traces of serum. Fresh medium was pipetted onto 
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the cells that were detached by pipetting up and down extensively and by slightly hitting the 
flask. Cells were collected into a falcon and centrifuged at 1500 rpm for 5 min. The cell pellet 
was resuspended in 1 ml of fresh medium, and a syringe was used to de-aggregate cell clusters. 
Appropriate aliquots of cell suspension were transferred into flasks according to the required 
split ratio.  
 
For storage, cells were suspended in freezing medium (90% FBS, 10% DMSO) and aliquotted 
into freezing phials at a density of about 2 x 10
6
 cells/ml. For a slow cooling process, freezing 
phials were placed in an isopropanol freezing container and placed to -80°C for 24 h. The 
following day, phials were transferred into a nitrogen tank for long-term storage. Thawing of 
cells was performed rapidly by incubation in a water bath at 37°C for 5 min. Afterwards, cells 
were washed immediately and resuspended in fresh prewarmed cell culture medium.  
 
4.2.2.2   Generation of GFP-expressing NmeCas9 targeting DNA constructs 
For the selection of transfected cells by cell sorting, a GFP cassette was introduced into the 
pSimpleII-U6-tracrRNA-U6-BsmBI-NLSNmCas9-HA-NLS(s) (Addgene #47868, Plasmid map 
1), which expresses NmeCas9, tracrRNA and a U6-BsmBI cassette for the generation of the 
crRNA. The GFP cassette was amplified from the peGFP-N1 plasmid using primers containing 
EcoRV restriction sites on the 5’ (Table 3) in a reaction mix containing 15 ng of plasmid DNA, 
1 µl of Phusion High-Fidelity DNA Polymerase, 1  µl dNTPs, 2 µl of 5X Phusion HF Buffer. 
The amplification was carried out in a PCR thermal cycler using the following program: 30s at 
98°C, 5 cycles of 10s at 98°C, 20 s at 59°C, 30s at 72°C, followed by 23 cycles of 10s at 98°C, 
20 s at 56°C, 30s at 72°C following a final 10 min extension step at 72°C. The amplified DNA 
fragment was gel purified and digested with EcoRV. The pSimpleII-U6-tracrRNA-U6-BsmBI-
NLSNmCas9-HA-NLS plasmid was digested with SmaI. Both fragments were ligated to 
generate the pSimpleII-U6-tracrRNA-U6-BsmBI-NLSNmCas9-HA-NLS-CMV-GFP plasmid 
(Plasmid map 2).  
 
A 24-nt-guide RNA (gRNA) was designed to target Exon 5 of Ntrk1 with the design tool 
available at Benchling (www.benchling.com) using the rat genome assembly rn6 (Rattus 
norvegicus, Rnor_6.0). This online based tool takes an input sequence, identifies and ranks 
suitable target sites, and computationally predicts off-target (OT) sites for each intended target 
based on the specificity analysis performed in Hsu et al, 2013 (138) as well as an activity score 
for each sgRNA based on Doench et al. 2014 (139) (high scores reflect higher specificity).  
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Afterwards, the pSimpleII-U6-tracrRNA-U6-BsmBI-NLSNmCas9-HA-NLS-CMV-GFP 
plasmid was digested with BsmbI, and the linearized vector was gel purified. A pair of partially 
complementary DNA oligos containing the 24-nt-gRNA and the processed crRNA sequence 
with four nucleotide overhangs compatible with those generated by BsmbI was ordered. As the 
U6 promoter requires a 5’ guanine (G) to start transcription, the first nucleotide of the gRNA 
sequence was replaced by a G (Table 3). To be cloned into the vector, partially complementary 
oligos were annealed. First, stock solutions of the oligos were prepared to a final concentration 
of 100 pmol/µl. Next, 200 µl of paraffin oil were added on top of a solution containing 30 µl of 
each forward and reverse oligos, placed in boiling water, and let cool for at least 3 hr. The 
annealed oligos were then used for ligation with the linearized plasmid. The construct was 
further sequenced to check for correct insertion.  
 
 
4.2.2.3   Transfection of NmeCas9, trRNA, and crRNA expressing plasmid into PC12 cells 
For transient protein overexpression, cells were transfected with pSimpleII-U6-tracrRNA-U6-
crRNA (Exon 5 Ntrk1) NLSNmCas9-HA-NLS-eGFP using Lipofectamine®2000 transfection 
reagent. Cells were seeded in 10-cm-culture-dish and allowed to reach about 80% confluence 
while maintained in cell culture medium. On the day of transfection, cells were washed three 
times with Opti-MEM®. After 2 hr incubation in Opti-MEM® containing 1 % P/S, cells were 
transfected with a solution of 10 μg of DNA and 10 µl of Lipofectamine®2000 prepared in 
Opti-MEM®. Following incubation for 4 hr with the transfection mixture, the medium was 
replaced with fresh medium.  
 
4.2.2.4   Cell sorting  
48 hr post-transfection cells were harvested, washed three times in DPBS, and incubated on ice. 
Before sorting, cells were incubated for 5 min in DPBS with 2% FBS containing 4,6-
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Diamidino-2-phenylindole (DAPI; 0,1µg/ml) to exclude dead cells. Cells were sorted in a BD 
FACS ARIAIII flow cytometer (BD Biosciences, USA). GFP-positive cells were collected on 
culture media, and serial dilutions were made to reach a concentration of 10 cells per ml. 
Afterwards, cells were seeded on ten 96-well-plates coated with 0.1 mg/ml poly-D-lysine 
hydrobromide for clonal isolation.   
 
4.2.2.5   CRISPR-genome-edited-PC12-cells genotyping 
For DNA extraction, 96-well-plate replica plates were generated containing single clones. Cells 
were washed two times with DPBS and 10 µl QuickExtract™ DNA Extraction Solution was 
used to extract DNA by pipetting up and down. The DNA was incubated for 6 min at 65˚C 
followed by 2 min at 98˚C, and the concentration and purity were assessed by absorbance at 
260 nm and 280 nm. Samples were diluted in low TE buffer (10 mM Tris-HCl, 0.1 mM EDTA) 
to reach a concentration of 200-400 ng/µl. The resulting DNA was used as a template for PCR 
amplification using two primers spanning the gRNA cut site (Ntrk1_Exon5_F: 5´-TTCTGCC 
TAGACCCCTTGGT-3´; Ntrk1_Exon5_R:5’-ATCTAAGTGTGGGCTGGTGAG-3’; product 
size: 409 bp). 2.5 μl DNA were used in a single PCR mix containing 0,1 µl of HotStarTaq Plus 
DNA Polymerase, 0.5 µl dNTPs, 2 µl of 10X QIAGEN PCR Buffer, and 1 µl of each primer. 
The amplification was carried out in a PCR thermal cycler using the following program: 5 min 
at 95˚C, 40 cycles of 20s at 95˚C, 20s at 64˚C, 35s at 72 ˚C followed by a final 10 min 
extension step at 72˚C. 15 µl of the amplified DNA was mixed with 5 µl of 5x DNA loading 
buffer and separated on a 2% agarose gel and 5 µl were used for sequencing. PCR amplified 
products were also analysed by non-denaturating polyacrylamide gel electrophoresis (PAGE) as 
described in section 4.2.1.6. 
 
4.2.2.6   Off-target analysis 
Potential off-target (OT) sites in the rat genome (Rattus norvegicus, Rnor_6.0) were identified 
and ranked using the design tool from Benchling (www.benchling.com), which allows for up to 
four mismatches in the target gRNA sequence. Also, COSMID (https://crispr.bme.gatech.edu/) 
(140), which enables the identification of OTs with up to three base mismatches without 
insertions or deletions and two base mismatches with either an inserted or deleted base (bulge), 
was used. Specific primers for each OT were designed (Table 4), and PCR amplification was 
carried out from DNA of the two clones presenting a homozygous deletion to determine if any 
mutations or changes occurred in these sites. For each PCR reaction, 2.5 μl DNA were used in a 
single PCR mix containing 0,1 µl of HotStarTaq Plus DNA Polymerase, 0.5 µl dNTPs, 2 µl of 
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buffer and 2 µl of each primer pair mix. The amplification was carried out in a PCR thermal 
cycler using the following program: 5 min at 95°C, 40 cycles of 30s at 95°C, 30 s at 57°C (for 
OT-1) or 59°C (for OT-2), 30s at 72°C, followed by a final 10 min extension step at 72°C. 15 
µl of the amplified DNA was mixed with 5 µl of 5x DNA loading buffer and separated on a 2% 
agarose gel and 5 µl were used for sequencing (see section 4.2.1.11). 
 
 
 
4.2.2.7   Gene expression analysis 
To compare the expression of Ntrk1 between wild-type and genetically modified clones, RNA 
was extracted from cells, and complementary DNA (cDNA) was generated according to section 
4.2.1.12 and 4.2.1.14 respectively. To have a quantitative estimation of gene expression, 
quantitative real-time PCR (qPCR) amplification of WT and KO-PC12-cells cDNA was 
performed using a Bio-Rad C1000 Thermal Cycler-CFX96 Real-Time system (Bio-Rad). All 
samples were run in triplicate in a final volume of 5 µl containing 1 µl of cDNA, 1 µM of 
primers and SsoAdvanced™ Universal SYBR® Green Supermix (BioRad). Before qPCR, a 
5 min enzyme activation step was done at 95°C. The qPCR protocol consisted of 10s 
denaturation at 95 °C, 15s at annealing temperature at 60 °C, 30 s elongation at 72 °C for 45 
cycles. The annealing temperature was confirmed by the melting curve.  
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4.2.2.8   Sequencing and segregation studies 
All patients analysed presented the minimal clinical features of HSAN-IV. Written informed 
consent was given by the patients and the parents. Genomic DNA was extracted from 
peripheral blood samples of the affected individuals and their parents (when available). Next-
generation sequencing (NGS-panel analysis) was performed and included the exons and intron–
exon boundaries of transcript variant 2 of NTRK1 (RefSeq ID NM 002529.3), which is the full-
length isoform and thought to be the main variant expressed in neuronal tissue (141).  Direct 
bidirectional Sanger sequencing of the amplified DNA fragments harbouring putatively 
pathogenic mutations was performed. The resulting sequences were analysed using the multiple 
sequence alignment tool included in SnapGene® software (from GSL Biotech; available at 
www.snapgene.com) and compared with the current reference sequence for NTRK1 in the 
NCBI database (NM_002529.3), corresponding to the amino sequence NP_002520.2. 
Sequencing reactions and alignments to the reference human transcriptome were repeated 
twice. The level of evolutionary conservation of the affected residues was analysed using 
Protein Blast  (https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins) (142). The relevance of 
identified variants was evaluated by online prediction tools including the Human Gene 
Mutation Database (HGMD, http://www.biobase-international.com/) and in-silico pathogenicity 
programs Mutation Taster (http://www.mutationtaster.org/) (143), PolyPhen-2 (144) 
(http://genetics.bwh.harvard.edu /pph2/) and by SIFT (145) 
(http://sift.jcvi.org/www/SIFT_enst_submit.html). Allele frequency of the variants was 
determined using ExAC, dbSNP, EVS, 1000genomes. 
 
4.2.2.9   Cloning of NTRK1 expression constructs 
The wild-type full-length human NTRK1 (RefSeq ID NM 002529.3) construct was obtained 
from GenScript (Plasmid map 3). A C-terminal myc-tag was introduced into this plasmid by 
site directed mutagenesis using the NTRK1-myc forward and reverse primers (Table 6). Briefly, 
20 ng of pCI-neo-NTRK1 plasmid were used as template for PCR amplification of a 471 bp 
fragment using Herculase II fusion Polymerase. The amplification was carried out in a PCR 
thermal cycler using the following program: 2 min at 95°C, 40 cycles of 20 s at 95°C, 30 s at 
62°C, 30s at 72°C followed by a final 3 min extension step at 72°C. The PCR product and the 
pCI-neo-NTRK1 were digested with MluI and EcoRV and gel-purified. A ligation was 
performed to generate the pCI-neo-NTRK1-myc (Plasmid map 4) plasmid.  
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To produce the mutant constructs, the pCI-neo-NTRK1-myc was used as template for the 
amplification of two smaller fragments to introduce the desired mutations. The reaction was 
performed in a 50 µl final volume containing 15 µg plasmid, 10 µl 5× Herculase II Reaction 
Buffer, 0.5 µl 100 mM dNTPs, 1.25 µl of each primer (Table 6) and 0.5 µl of Herculase II 
Fusion DNA Polymerase. The amplification was carried out in a PCR thermal cycler using the 
following program: 2 min at 95°C, 40 cycles of 20s at 95°C, 30s at 62 or 61°C, 30s or 45s at 
72°C followed by a final 3 min extension step at 72°C. The PCR products were gel-purified and 
used as template for a second PCR with similar conditions to generate a longer fragment. These 
fragments as well as the pCI-neo-NTRK1-myc plasmid were digested with XcmI and EcoRV 
and ligated to generate three mutant pCI-neo-NTRK1-myc plasmids termed: pCI-neo-NTRK1-
myc-I, pCI-neo-NTRK1-myc-II, pCI-neo-NTRK1-myc-III, according to the respective mutation.  
 
4.2.2.10   Transfection of NTRK1 expression constructs into PC12 cells 
In order to achieve a high transfection efficiency, PC12 cells were transfected using the Amaxa 
SF cell line 4D-Nucleofector X Kit in a 4D-Nucleofector™ X-Unit (Lonza). Cells were seeded 
onto T-75 cm
2
 flasks coated with 0.1 mg/ml poly-D-lysine hydrobromide. On the day of 
transfection, cells were detached, collected into a falcon and centrifuged at 1500 rpm for 5 min. 
The cell pellet was resuspended in 1 ml of DPBS, and a syringe was used to de-aggregate cell 
clusters. For each 20 µl transfection reaction, 4 x 10
5 
cells were centrifuged in 1.5 ml tubes and 
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resuspended in a solution containing 2 µg (1 µg/µl) of plasmid DNA, 16.4 µl of SF 
Nucleofector® Solution plus 3.6 µl of Supplement 1. The cell suspension was transferred into a 
cuvette and placed inside the Nucleofector® Cuvette Holder, and the Nucleofector® Program 
EO-100 was applied. Once the program finished, 100 µl of warm culture medium was added to 
the cuvette followed by incubation for 5 min at RT. Afterwards, the cells were transferred into 
12 or 6 well plates, and fresh medium was added. For a 100 µl reaction, 10 µg (1 µg/µl) of 
plasmid DNA, 82 µl of SF Nucleofector® Solution plus 18 µl of Supplement 1 were used to 
transfect 2 x 10
6
 cells.  
 
4.2.2.11   Neurite outgrowth assay 
PC12 cells were seeded on coverslips coated with 0.1 mg/ml poly-D-lysine hydrobromide and 5 
ug/ml laminin to promote adhesion. Cells were treated with 100 ng/ml NGF in RPMI 
supplemented with 1% HS for 3 or 7 days, with media being replaced every 3 days. Cells were 
then washed in DPBS and fixed in warm 4% paraformaldehyde, permeabilised (PBS, 0.25% 
Triton-X at RT for 20 min), blocked (DPBS, 0.25% Triton-X and 5% normal goat serum at RT 
for 1 hr) and stained overnight at 4°C with α-Acetylated tubulin and anti-myc antibodies. The 
following day cells were stained with secondary antibody (diluted 1:2000 in blocking solution, 
2 hr at RT) and nuclei were stained with Hoechst-33258 (1:10000 in DPBS, 10 min at RT) and 
slightly washed. Cells were imaged with a Leica TCS SP5 confocal scanning fluorescence 
microscope using a 20X or 40X objective. Cells were analysed using the ImageJ software. A 
neurite was identified as being more than twice the cell body diameter. Neurite length per cell 
was quantified as the longest neurite measured for each cell (146). Percentage of cells bearing 
neurites was calculated from the same data as the number of cells with neurites divided the total 
number of cells in that field of view (for WT vs KO cells).  
 
4.2.2.12   Immunocytochemistry  
48 hr post-transfection, HeLa cells were fixed with fixative solution (4% paraformaldehyde 
(PFA) in DPBS, pH 7.4) at RT for 20 min and rinsed three times with DPBS for 5 min. For 
permeabilization, cells were incubated with PBS, 0.25% Triton-X at RT for 20 min. Next, cells 
were incubated with blocking solution (DPBS, 0.25% Triton-X and 5% normal goat serum) at 
RT for 1 hr and incubated with primary antibody (see Table 1) diluted in blocking solution at 
4°C overnight. For co-stainings, a mixture of primary antibodies was applied. The following 
day, cells were washed three times with DPBS for 10 min each. Afterwards, secondary 
antibodies (see Table 1) diluted 1:2000 in blocking solution were incubated at RT for 1 hr 
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followed by a washing step with DPBS. Following nuclei staining with Hoechst-33258 
(1:10000 in DPBS) for 10 min at RT, cells were washed three times with DPBS. Finally, 
coverslips with stained cells were mounted with Fluoromount-G (Southern Biotech) on 
microscope slides and analysed with a Leica TCS SP5 confocal scanning fluorescence 
microscope equipped with a 63x objective.  
 
4.2.2.13   Cell stimulation with NGF  
Upon stimulation with Nerve Growth Factor (NGF), wild-type PC12 differentiate into neurone-
like cells due to the activation of diverse signalling pathways. For short-term stimulation of up 
to 30 min, the cells were starved for four hours in serum-free medium (RPMI containing 0.25% 
BSA). 30 min before stimulation with NGF (100 ng/ml), the medium was substituted with 
HEPES-buffered solution containing 0.25% BSA and cells were incubated at 37 ˚C without 
CO2. NGF was added to this medium to a final concentration of 100 ng/ml. After 0, 5, 10 or 
30 min, the cells were washed with ice-cold wash-lysis buffer (50 mM Tris base, 2 mM EDTA, 
1mM EGTA, 50 mM NaF, 100mM Na4P2O7, 1 mM Na3VO4, 1mM DTT, pH 7,4) and were 
incubated with lysis buffer (50 mM Tris base, 2 mM EDTA, 1mM EGTA, 50 mM NaF, 
100mM Na4P2O7, 1 mM Na3VO4, 1mM DTT, 1% Triton-X-100, 0,1 % SDS, 0.2 M PMSF, 10 
µl/ml Protease Cocktail inhibitor) on ice for 15 min. The cells were then scraped off the plastic 
surface, and the collected cell lysates were centrifuged (700 g, 6 min, 4°C). The supernatant 
fraction was transferred to a new tube and stored at -20 C.  
 
4.2.2.14   SDS-PAGE and Western blotting 
Western blot analysis was performed together with Dr Katrin Spengler. Protein concentration 
was determined using the Lowry method and analysed spectrophotometrically. Afterwards, 3x 
Laemmli buffer (186 mM Tris pH 6.8, 10 mM EDTA, 15 % Glycerol, 9 % SDS, 6 % 2-
Mercaptoethanol, 0.03 % Bromophenol blue) was added and proteins were denaturated for 5 
min at 95 °C under gentle shaking. The proteins were separated by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) according to their size together with a molecular size marker. 
SDS-gels consisting of stacking and a 7.5 % separating gel were run with electrode buffer (25 
mM Tris, 192 mM Glycine, 1 % SDS) at 45 mA per gel for 2 hr. After electrophoresis, the 
separated proteins were transferred to a PVDF membrane by a wet-blot system in transfer 
buffer (25 mM Tris base, 192 mM glycine, 20 % methanol). The Western blot sandwich 
contained three pieces of Whatman filter paper overlaid by a methanol-activated PVDF 
membrane, the SDS-gel and another three pieces of Whatman filter paper. The transfer was 
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performed at 750 mA per gel for 100 min. Afterwards, the membranes were blocked by 
incubation in blocking solution containing 5 % milk in Tris-buffer saline (10 mM Tris pH 7.6, 
1.5 m NaCl) supplemented with 0.1 % Tween-20 (TBS-T) at RT for 1 hr. Next, membranes 
were incubated in primary antibody solution (5 % BSA in TBS-T and primary antibody 
according to Table 2) under gentle agitation at 4 °C overnight. The next day, the membrane was 
washed four times with TBS-T for 5 min each followed by incubation in secondary antibody 
solution (5 % milk in TBS-T and secondary antibody according to Table 2) at RT with agitation 
for 60 min. After three more washing steps in TBS-T for 5 min each and two washing steps in 
TBS, immunodetection was performed by enhanced chemiluminescence (ECL). The membrane 
was incubated with ECL substrate for 1 min. The horseradish peroxidase enzyme linked to the 
secondary antibody cleaves the chemiluminescent agent producing luminescence. The 
luminescence was detected by a photosensitive film (Fujifilm). For reprobing, the membranes 
were washed and incubated in stripping buffer (62.5 Tris pH 6.7, 2 % SDS, 100 mM 2-
Mercaptoethanol) for 35 min at 54°C under gentle shaking. Afterwards, membranes were 
washed and blocked again as described followed by incubation in another primary antibody 
solution. Finally, the films were scanned, and the protein bands were quantified with ImageJ 
software.  
 
4.2.3   Generation of Scn10a/Scn11a double-knockout mice with CRISPR  
 
4.2.3.1   Cloning of targeting sequences into pX330 plasmids and generation of sgRNAs by 
in vitro transcription 
The bicistronic expression vector pX330-U6-chimeric_BB-CBh-hSpCas9 (Addgene #42230, 
Plasmid map 5) expressing human codon-optimized Cas9 (hSpCas9) and an sgRNA cloning 
site (73) was digested with BbsI, and the linearized vector was gel purified. A pair of partially 
complementary DNA oligos, containing the 20-nt-sgRNA sequence and 4-nt-overhangs 
compatible for cloning into the vector, was designed for each targeting site using CRISPR 
Design Tool (www.crispr.mit.edu) (138) or Benchling (www.benchling.com) (Table 7). Both 
online based tools take an input sequence, identify and rank suitable target sites, and 
computationally predict OT sites for each intended target based on the specificity analysis 
performed in Hsu et al., 2013 (138). Benchling also provides an activity score for each sgRNA 
based on Doench et al. 2014 (139). As the U6 promoter driving the expression of the sgRNA 
requires a 5’ guanine (G) to start transcription, an additional G was added to the front of the 
sgRNA sequence in cases in which the target did not start with a G (Figure 7). 
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To be cloned into the pX330 vector, partially complementary oligos need to be annealed. First, 
stock solutions of the oligos were prepared to a final concentration of 100 pmol/µl. Next, 200 µl 
of paraffin oil was added on top of a solution containing 30 µl of each forward and reverse 
oligos, placed in boiling water, and let cool for at least 3 hr. The annealed oligos were then used 
for ligation with the digested pX330 plasmid. The respective construct was further sequenced to 
check for correct insertion.  
 
For injection into zygotes, the sgRNA needs to be in vitro transcribed. In vitro transcription 
requires a purified linear DNA template containing a promoter, a buffer system that includes 
DTT and magnesium ions, ribonucleotide triphosphates, and an appropriate phage RNA 
polymerase. pX330 plasmids lack a T7 promoter site, which is needed by the T7 RNA 
Polymerase to start transcription; thus, a 120-bp PCR product containing T7 promoter, target 
and scaffold sequence is used as template for the in vitro transcription (IVT). The fwr primer 
(Table 7) introduces the T7 promoter sequence plus 2 G nucleotides (or only one in case the 
sgRNA sequence starts with G), needed for transcription initiation, into the sgRNA DNA 
template while the rev primer binds to the sgRNA scaffold (Figure 7) (147). 
 
 
 
 
 
 
Therefore, the pX330 plasmid was diluted to a final concentration of 15 ng/µl and used as 
template for the amplification of the sgRNA-containing PCR fragment. The reaction was 
performed in a 50 µl final volume containing 1 µl of the diluted plasmid, 10 µl 5× Herculase II 
Reaction Buffer, 0.5 µl 100 mM dNTPs, 1.25 µl T7-sgRNA fwr primer and 1.25 µl T7-sgRNA 
Rev primer and 0.5 µl of Herculase II Fusion DNA Polymerase. The amplification was carried 
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out in a PCR thermal cycler using the following program: 2 min at 95°C, 40 cycles of 20s at 
95°C, 30s at (Annealing Temp of the T7-sgRNA fwr primer, see Table 7) °C, 30s at 72°C 
followed by a final 3 min extension step at 72°C. The PCR product was gel purified and 
concentrated with DNA Clean & Concentrator™ Kit following the manufacturer’ s instructions 
and eluted into UltraPure DNase/RNase-free distilled water.  
 
The IVT was done using the MEGAshortscript™ T7 Transcription Kit following the 
manufacturers’ instructions. The reaction was performed in a 20 µl volume containing 8 µl 
dNTPs mix, 2 µl T7 10X Reaction Buffer, 2 µl T7 Enzyme Mix, 8 µl of PCR template (200 ng 
total) and 2 µl of UltraPure DNase/RNase-free distilled water. The mixture was incubated at 
37°C for at least 4 hr. To remove the DNA template, 1 µl of TURBO DNase was added to the 
reaction mix and incubated for 15 more minutes at 37°C. The RNA was purified using the 
MEGAclear™ Transcription Clean-Up Kit. Briefly, 80 µl of Elution Solution was added to the 
RNA, followed by 350 µl of Binding Solution Concentrate and 250 µl of 100% ethanol. The 
mixture was added onto the Filter Cartridge and centrifuged for 1 min at full speed. Washing 
was done by adding two times 500 µl Wash Solution. For elution, 50 µl of pre-heated Elution 
Solution at 95° C was applied to the centre of the Filter Cartridge, centrifuged for 1 min at RT 
at max speed. The concentration of RNA was assessed by UV Absorbance at 260 nm. Around 
500 ng of denaturated RNA (10 min at 75°C) were loaded on a 2 % gel to confirm integrity 
before injection.  
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4.2.3.2   Plasmid DNA in vitro cleavage assay  
To avoid delivery of ineffective single guide RNAs (sgRNAs) to the mouse zygotes for Cas9-
mediated genome editing, a simple assay to test the efficacy of the different sgRNAs in vitro 
based on Jinek et al. 2013 was performed. Initially, a PCR fragment containing the target 
sequence was amplified with the designed genotyping primers (Table 10) and cloned into 
pCR®2.1 TOPO® vector as described in section 4.2.1.10. A minipreparation of plasmid DNA 
was performed for five colonies, checked for the incorporation of insert by restriction digestion 
and further sequenced. Afterwards, the plasmid was linearized with PscI and gel purified. The 
DNA concentration was set to a minimum of 100 ng/µl. In order to get the SpCas9 protein, 
HEK293T cells were seeded in a 10 cm-culture-dish and allowed to reach about 80% 
confluence and maintained in DMEM (Dulbecco's Modified Eagle Medium containing high 
glucose, GlutaMAX™ Supplement, pyruvate, plus 10% FBS, 1 % P/S). Then, cells were 
transfected with 10 μg of empty pX330-U6-chimeric_BB-CBh-hSpCas9 plasmid expressing 
hSpCas9 using Lipofectamine® 2000 Reagent. First, the DNA and 15 µl Lipofectamine were 
diluted in 500 µl Opti-MEM® (Minimum Essential Medium) in separate tubes. After 5 min 
incubation, both solutions were mixed and further incubated for 20 min at RT allowing the 
formation of liposomes that entrap the DNA. Following addition of fresh medium to the cells, 
the transfection mixture was added drop-wise on top of the cells and incubated for 48 h at 37˚C. 
On the day of the assay, cells were washed three times with DPBS and collected on ice with a 
cell scraper in 1 ml of DPBS containing 100 µl of Protease Inhibitor Cocktail. Cells were 
homogenised by passing the solution ten times through a sterile 1 ml syringe with a 22 G x 1 ¼ 
needle, centrifuged 1 min at 14,000 rpm at 4°C for 1 min. The supernatant fraction was used to 
prepare four reaction tubes as described in Table 4. The tubes were incubated for 4 hr at 37°C 
in a shaking incubator with 10 mM MgCl2, as Cas9 is a Mg
2+
-dependent endonuclease with 3’-
5’ exonuclease activity. The reactions were stopped by adding 10 µl of 5X DNA loading buffer, 
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purified with the Gel DNA Recovery Kit and further loaded on a 1% agarose gel. Only in tube 
number 3, where all the components needed by SpCas9 to produce a DSB in the DNA are 
present (SpCas9, sgRNA, MgCl2, and the target sequence), we expect to see two bands as result 
of an efficient cut. The other tubes are the respective negative controls.  
 
 
4.2.3.3   One-cell embryo injection  
For the injection of CRISPR constructs, a large number of zygotes is needed. Through the 
administration of gonadotropins, female mice can be induced to ovulate a greater number of 
eggs than normal, a process called superovulation. For this purpose, approximately ten 
C57BL/6 female mice of 21-28 days (body weight of 12-14 grammes) were injected 
intraperitoneally (i.p.) with a dose of 5.0 international units (IU) of pregnant mare’s serum 
gonadotropin (PMSG) between 1:00 and 3:00 PM of day 1 to give the best yield of fertilised 
eggs. On day 3, the mice received an IP injection of human chorionic gonadotropin (hCG). 
Immediately following injection, superovulated females were mated to C57BL/6 males. 
Ovulation takes place approximately 12 hours after the HCG injection, at which time the eggs 
can be fertilised (149). On day 4, fertilised eggs were collected from oviducts and kept in 
Krebs-Ringer Bicarbonate Buffer at 37°C until both female and male pronuclei are visible. At 
this point, zygotes were then transferred to Krebs-Ringer Bicarbonate Buffer, 20 mM HEPES, 
and the pX330-U6-chimeric_BB-CBh-hSpCas9 expressing hSpCas9 and sgRNA or 
PrecisionX™ Cas9 SmartNuclease mRNA (Eukaryotic version) plus the IV transcribed sgRNA 
mixture was injected into the pronucleus or cytoplasm respectively (Table 9). All the injected 
zygotes were cultured in M16 medium covered with mineral oil overnight, and only two-cell-
stage embryos were transferred into the oviduct of pseudopregnant foster mothers (0.5 days 
post coitus) (150).  
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4.2.3.4   Mouse genotyping 
DNA was extracted from tail biopsies using the HotSHOT method (151). Briefly, a 0.2 mm-tail 
biopsy was incubated with 50 μl of alkaline lysis buffer (25 mM NaOH, 0.2 mM EDTA) for 60 
min at 98°C while shaking. Samples were neutralised with 50 μl of neutralisation buffer (40 
mM Tris-HCl). For genotyping PCR, 2.5 μl DNA were used in a single PCR mix containing 0,1 
µl of HotStarTaq Plus DNA Polymerase, 0.5 µl dNTPs, 2 µl of buffer and two exon-specific 
primers with the respective sequence (Table 10). The amplification was carried out in a PCR 
thermal cycler using the following program: 5 min at 95°C, 40 cycles of 30s at 95°C, 30 s at 
59°C, 30s at 72°C, followed by a final 10 min extension step at 72°C. 15 µl of the amplified 
DNA was mixed with 5 µl of 5x DNA loading buffer and separated on a 2% agarose gel and 5 
µl were used for sequencing (see section 4.2.1.11). PCR amplified products were also analysed 
by non-denaturating polyacrylamide gel electrophoresis (PAGE) as described in section 4.2.1.6. 
In addition, large fragment PCR amplification was performed using Herculase II fusion 
Polymerase as outlined in section 4.2.2.10. 
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4.2.3.5   Off-target analysis 
Off-target (OT) sequences were computationally identified and ranked using the online design 
tool from Benchling (www.benchling.com), which allows for up to four mismatches in the 
target gRNA sequence (138). For each sgRNA, primers for the top five OT sequences and OT 
coding regions, if detected, were designed (Table 11). PCR amplification was carried out from 
DNA of the founder chimaera and the two F1 founder animals to determine if any mutations or 
changes occurred in OT sites. For each PCR reaction, 2.5 μl DNA were used in a single PCR 
mix containing 0,1 µl of HotStarTaq Plus DNA Polymerase, 0.5 µl dNTPs, 2 µl of buffer and 1 
µl of each specific primer pair. The amplification was carried out in a PCR thermal cycler using 
the following program: 5 min at 95°C, 40 cycles of 30s at 95°C, 30 s at (Annealing 
Temperature of the primers), 30s at 72°C, followed by a final 10 min extension step at 72°C. 15 
µl of the amplified DNA was mixed with 5 µl of 5x DNA loading buffer and separated on a 2% 
agarose gel and 5 µl were used for sequencing (see section 4.2.1.11).  
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4.2.3.6   Gene expression analysis 
To analyse the expression of Scn10a and Scn11a in mouse tissue, RNA was extracted from 
DRGs tissue, and complementary DNA (cDNA) was generated according to section 4.2.1.13 
and 4.2.1.14 respectively. In order to have a quantitative estimation of gene expression, 
quantitative real-time PCR (qPCR) amplification of WT and KO cDNA was performed using a 
Bio-Rad C1000 Thermal Cycler-CFX96 Real-Time system (Bio-Rad). All samples were run in 
triplicate in a final volume of 5 µl containing 1 µl of cDNA, 1 µM of primers and 
SsoAdvanced™ Universal SYBR® Green Supermix (BioRad). Prior to qPCR, a 5 min enzyme 
activation step was done at 95 °C. The qPCR protocol consisted of 10s denaturation at 95 °C, 
15s at annealing temperature at 58 °C, 30 s elongation at 72 °C for 45 cycles. The annealing 
temperature was confirmed by the melting curve.  
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4.2.4 Electrophysiological studies of SCN10A and SCN11A wild-type and mutant 
constructs. 
Electrophysiological studies were carried out by Dr Enrico Leipold. Cell culture and 
transfection of ND7/23 cells, isolation and transfection of mouse DRG neurones, as well as 
electrophysiological methods, are described in Leipold et al. 2015. (65) 
 
4.2.5   Mouse studies 
All animal experiments were approved by the local administrative institution (Thüringer 
Landesamt für Verbraucherschutz, Bad Langensalza, Germany) and the experimental 
procedures were performed in accordance with the guidelines established by the animal welfare 
committee of the State of Thuringia. 
 
4.2.6   Statistical analysis 
Data are presented as mean ± SEM in the figures. The statistical test applied for p-value 
calculation is noted in the legends of the respective figures. One- or Two-way ANOVA or 
parametric two-tailed Student's t-test were applied after confirming a parametric distribution by 
Normal Q-Q-Plots. For non-parametric distributed data, the Mann-Whitney-U-test was applied. 
Levels of significance were set as following: *** p < 0.001; ** p < 0.01, * p < 0.05.
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5. Results  
The results section is divided into two parts. The first part is dedicated to the creation of a 
cellular model for the functional characterization of novel missense mutations in the NTRK1 
gene whereas in the second part the generation of an SCN10A and SCN11A double-knockout 
mouse model is described.  
 
5.1   Generation of a cellular model for the functional characterization of novel missense 
mutations in the NTRK1 gene 
 
5.1.1   Putative newly identified mutations in NTRK1 causing HSAN-IV 
In the present study, three cases with a typical hereditary sensory and autonomic neuropathy 
type IV (HSAN-IV) phenotype, in which parents had no features of the disease, are reported. 
All patients exhibited the characteristic symptoms of HSAN-IV (8–10), including congenital 
insensitivity to noxious stimuli and temperature, anhidrosis (inability to sweat), muscular 
hypotonia, global cognitive delay, self-mutilations of the tongue and fingertips accompanied 
by painless fractures, and episodes of unexplained high fever. All patients were from India. 
Using next-generation sequencing panel analysis including the full-length NTRK1 (RefSeq ID 
NM 002529.3) isoform expressed in neuronal tissue (141), novel homozygous missense 
mutations were identified in affected individuals. Additionally, sequencing of both parents 
confirmed that the mutations segregated as expected for an autosomal recessive disorder. 
However, for patient one no parental data was available. Of note, no mutation was detected in 
the NGF gene (RefSeq ID NM 002506.2), which may cause a similar phenotype (6). The 
putative missense mutations were c.1095C>A, c.1514T>A, and c.1898A>G (RefSeq ID NM 
002529.3), leading to the NTRK1 protein changes p.N365K, p.I505N, and p.Q633R 
respectively. Nucleotide numbering uses +1 as the first nucleotide of the ATG translation 
initiation codon (codon #1) in the reference sequence. To date, no variation at these positions 
is reported in the Exome Variant Server (http://evs.gs.washington.edu/EVS/), the 1000 
Genomes Server, dbSNP (http://www.ncbi.nlm.nih.gov/SNP/), or the ExAC database 
(http://exac.broadinstitute.org). The mutation in patient one causes a single amino acid change 
in the second immunoglobulin –like domain of NTRK1, while in patients two and three the 
missense mutations localise within the juxtamembrane domain and the tyrosine kinase 
domain respectively (Figure 8B). All mutations affect evolutionarily conserved residues and 
were predicted to be pathogenic by Mutation Taster, Polyphen and SIFT (Figure S1). 
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However, further evaluation of missense mutations requires functional studies to prove their 
pathogenicity. 
 
 
5.1.2   Efficient generation of Ntrk1-KO PC12 cells via CRISPR genome editing  
To study the effect of the NTRK1 mutants in a physiologically relevant cellular context, 
Ntrk1 was disrupted in PC12 cells using the CRISPR (clustered regularly interspaced short 
palindromic repeats)-Cas (CRISPR-associated protein) system. PC12 cells are derived from a 
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rat pheochromocytoma and can recapitulate neurite differentiation and neuronal signalling 
upon stimulation with NGF (134). In contrast, as illustrated in Figure 9A, in an Ntrk1-KO 
PC12 cell line, one should not expect neurite outgrowth or activation of signalling cascades 
upon NGF treatment, thus making it a good model for testing the NTRK1 mutants, which can 
be heterologously expressed in the system.  
 
 
′
′
′
 
The CRISPR-associated protein 9 (Cas9) nuclease catalyses a site-specific double-strand-
brake (DSB) in a desired target DNA sequence. Targeting of Cas9 to specific genomic loci is 
mediated by a short guide RNA (gRNA) sequence. Recognition of cleavage sites is 
determined by gRNA-DNA base pairing, and cleavage only occurs if the target site is 
followed by a protospacer-adjacent-motif (PAM), a three-nucleotide sequence juxtaposed to 
the DNA complementary region. The DSB activates DNA repair enzymes that often disrupt 
the DNA sequence by generating insertions or deletions (indels) as well as substitutions near 
the cleavage site via the error-prone non-homologous end-joining (NHEJ) repair pathway (73, 
125). However, Cas9 can tolerate single-base mismatches, DNA insertions (DNA bulges) or 
deletions (RNA bulges) between the gRNA and the genomic target site, which have 
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significant implications to the targeting specificity of the enzyme as they can lead to 
undesired mutations (off-targets) (132, 152).  
 
In order to generate indels in the Ntrk1 gene, the Neisseria meningitides Cas9 (NmeCas9) was 
used, as it has been reported that it produces less off-target (OT) cleavage while achieving 
similar on-target activities than the Streptococcus pyogenes Cas9 in mammalian cells (131, 
132). In addition, the optimal SpCas9 PAM (5’-NGG) can be found approximately every 
eight bases in a random DNA sequence, while the optimal NmeCas9 PAM (5’-NNNNGATT) 
is present every 128 bases, thus reducing the number of potential OT sites (131).  
Therefore, a 24-nt-guide RNA was designed using the online design tool from Benchling 
(www.benchling.com) to target exon 5 of Ntrk1 (gNtrk1-Ex5; Figure 9B). As shown in Figure 
10A, wild-type PC12 (wtPC12) cells were transfected with a plasmid expressing NmeCas9, 
tracrRNA (transactivating crRNA), a cassette for the expression of the crRNA (CRISPR- 
RNA), where the gRNA was cloned, and GFP to enable selection of NmeCas9-expressing 
cells (131). Subsequently, cells were FACS-sorted 48 hr post-transfection (Figure 10B). GFP-
positive cells were initially seeded in a small dish to let them recover and later seeded on 96-
well-plates for single clone selection. 
 
To confirm that NmeCas9 introduced a DSB in the intended genomic locus, DNA was 
extracted from each clone and the genomic region flanking the cleavage site was PCR-
amplified and analysed by standard 2 % agarose gel electrophoresis (Figure 10C) as well as 
by non-denaturating polyacrylamide gel electrophoresis (PAGE; Figure S2). Surprisingly, 
none of the clones exhibited formation of heteroduplex DNA bands. However, as by this 
methods 1 bp indels cannot be detected, all clones were sequenced. Sequencing results 
showed that only 6 of the 30 PC12 clones analysed were genetically modified. As depicted in 
Figure 10D, all indels were found at the NmeCas9 cleavage site, indicating that the DSB 
occurred at the intended position, but at a relatively low frequency (20%). Clone #7 contained 
a 1 bp insertion (+1 bp; Figure S3). As shown in Figure 10E, two clones (#3 and #16) 
contained a homozygous 1 bp deletion (∆1 bp), which was also found in heterozygosity in the 
remaining modified clones (Figure S3). Interstingly, all the genetically-engineered clones had 
a similar rearrangement. A possible explanation for this observation is that cells were plated 
before clonal isolation, allowing cell proliferation and thereby causing clonal drifts. Still, this 
does not explain why the same ∆1 bp was found in both heterozygosity and homozygosity. 
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Thus, these results suggest that the genome context influences the repair mechanisms in 
favour of similar rearrangements.  
 
′
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5.1.2.1   Off-target analysis in CRISPR/Cas-mediated Ntrk1-KO PC12 cells 
OT cleavage can cause unwanted mutations and chromosomal rearrangements due to 
nonspecific hybridization of the guide strand to genomic DNA sequences. Therefore, 
potential OT-sites were predicted and ranked using the web-based tool COSMID (140) (Table 
S1) as well as the design tool available in Benchling (Table S2) and further analysed. Though 
other potential OTs than the predicted ones cannot be excluded, no mutation was found in 
undesired target sites in neither clone (Figure S4).  
 
5.1.2.2   Functional characterization of Ntrk1-KO PC12 cells  
The homozygous ∆1 bp found in clone #3 and #16 produces a frameshift in the coding 
sequence of Ntrk1 and is predicted to result in a premature stop codon in exon 6 (Figure 10F). 
To investigate whether Ntrk1 expression is absent in Ntrk1-KO PC12 clones, mRNA and 
protein expression levels were analysed under normal culture conditions (10% serum in the 
medium) and compared to wtPC12 cells. As expected, the high mRNA levels of Ntrk1 in 
wtPC12 cells were diminished in both Ntrk1-KO PC12 clones (qPCR), as shown in Figure 
11A. Ntrk1 gives rise to two different bands in western blot analysis. It is proposed that the 
lower band at ~110 kDa corresponds to the immature Ntrk1 that has not completed Golgi-
mediated processing of high-mannose N-glycans (153) while the upper band of ~140 kDa 
represents the fully glycosylated mature form present in the plasma membrane (PM). 
Moreover, it is known that intracellular Ntrk1 can spontaneously dimerize (154). As can be 
seen in Figure 11B, the upper band corresponding to the fully functional glycosylated isoform 
is absent in the KO cells (clone#3), suggesting that Ntrk1 is not functionally expressed in 
these cells (data shown for clone#3 only, see Figure 11C). However, a lower band was 
detected in both WT and KO cells, which may be unspecific. 
 
Next, the two major Ntrk1-signalling cascades triggered by NGF stimulation were 
investigated. Specifically, the phosphatidylinositol 3-kinase (PI3K) and the mitogen-activated 
protein kinase (MAPK) signalling pathways were analysed by detecting the specific 
phosphorylation of Erk 1/2 (extracellular signal-regulated kinase one and two) and Akt kinase 
(protein kinase B). As shown in Figure 11B, Western blot analysis revealed that both the 
expression levels of Erk 1/2 and Akt were comparable between wtPC12 and Ntrk1-KO-PC12 
cells clones. However, NGF-induced phosphorylation at the T202/Y204 sites of Erk 1/2 and 
T308 of Akt was not detected in the Ntrk1-KO PC12 clones.  
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To address neurite outgrowth of the Ntrk1-KO-PC12 line, cells were treated with NGF for 7 
days and compared to wtPC12 cells. As can be observed in Figure 12, the Ntrk1-KO cells do 
not show any sign of neurite outgrowth (only clone #3 is shown). Taken together, the data 
suggest that these cells are a good model for evaluating the effects of the NTRK1 missense 
mutations. 
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5.1.3   Glycosylation changes and downstream activation of MAPK and PI3K signalling 
pathways by NTRK1 mutants  
Next, the effects of the patient-related missense mutations on NTRK1 expression and 
activation of the PI3K and MAPK signalling pathways were analysed. Ntrk1-KO-PC12 cells 
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were transiently nucleofected with the respective wild-type and mutant NTRK1-cDNA 
constructs, and 24 hr post transfection cells were treated with NGF for different time points 
and subjected to protein extraction. As can be seen in Figure 13A, Western blot analysis of 
NTRK1 expression showed that similarly to the wtNTRK1, mutants p.I505N and p.Q633R 
had a functional membrane-bound NTRK1 isoform, as can be assessed by the presence of a 
band of ~140 kDa. In addition, all constructs, except p.I505N, showed increased expression of 
the ~110 kDa band that was previously proposed to be unspecific. Thus, it can be presumed 
that this band, expected to be the intracellular immature form of NTRK1, is overlapping with 
an unspecific band. Interestingly, mutant p.N365K showed a two-fold increase of intracellular 
NTRK1 compared to mock-treated cells but significantly reduced levels of the mature fully 
glycosylated form compared to wtNTRK1, indicating that this mutation might cause HSAN-
IV due to defective processing or trafficking to the PM (Figure 13B).  
 
Expression of the heterologous wtNTRK1 construct in Ntrk1-KO PC12 cells showed a similar 
ability to activate the PI3K and MAPK pathways than mock-transfected wtPC12 cells upon 
NGF stimulation (Figure S5). As shown in Figure 13, basal phosphorylation was detectable in 
untreated transfected cells due to NTRK1 self-activation caused by overexpression. In cells 
transfected with the wtNTRK1 construct, the level of Erk phosphorylation increased 
approximately 3-fold upon NGF stimulation, reaching a peak after 5 min and declined slightly 
after 30 min of treatment, while Akt phosphorylation increased with time of exposure to NGF, 
reaching ~3-fold increased at 30 min. In contrast, no Erk phosphorylation was detected upon 
NGF stimulation in cells transfected with mutant p.N365K. Additionally, Akt 
phosphorylation remained constant over time in these cells, indicating Akt is not activated in 
an NGF-dependent manner. These results support the hypothesis that this mutant is not able to 
mature and traffic correctly to the PM.  
 
In cells transfected with mutant p.I505N or p.Q633R, Akt signalling is activated similarly to 
wtNTRK1, suggesting this is not the main reason by which these mutants cause HSAN-IV. 
However, Erk phosphorylation decreases abruptly to basal levels at 30 min in both mutants. 
Upon NGF binding, NTRK1 interacts with p75
NTR
 and several adaptor proteins to facilitate 
signalling events (20). Additionally, NTRK1 is ubiquitinated and subsequently internalised 
into endocytic vesicles (155) and can be either sorted to lysosomes or recycled back to the PM 
(156, 157). The degradative pathway to lysosomes is characterised by down-regulation of the 
total number of receptors at the cell surface and decreased responsiveness to the ligand. 
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Recycling to the PM promotes functional resensitization and prolongation of cell surface–
specific signalling events (156). Most NTRK1 receptors at the cell surface are internalised by 
30 min of NGF treatment (158). In PC12 cells, internalisation of activated NTRK1-NGF 
complexes is required for the induction of neurite outgrowth but not for NGF-mediated 
survival. Indeed, activated NTRK1 receptors located at the cell surface promote cell survival 
via PI3K/Akt activation whereas NTRK1 receptors from internalised endosomes promote cell 
differentiation by preferential activation of Erk (159). Furthermore, persistent activation of 
the MAPK pathway is essential for NGF-induced morphological and biochemical 
differentiation of PC12 cells into a neuronal phenotype (160). Chen et al. reported that this 
effect is promoted by the activation of Rap1 (Repressor Activator Protein 1), a member of the 
Ras superfamily. They showed that after NGF treatment Ras activation is transient, while 
Rap1, which localises to endosomes together with the NTRK1-NGF receptor complex, 
activated Erk 1/2 from endosomes for prolonged periods of time (160). As both mutant 
receptors do not exhibit prolonged activation of Erk, it can be speculated that either NTRK1 
internalisation or its interaction with other proteins needed for persistent activation of the 
MAPK pathway is impaired in mutants p.I505N and p.Q633R (Figure 13 C). 
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Although all four constructs were nucleofected with the same amount of plasmid DNA, the 
different receptors seemed to be differentially expressed. Since the amount of receptor may 
influence activation of signalling pathways, Erk and Akt phosphorylation was first 
standardised to the endogenous Erk and Akt, respectively, and further normalised to the 
average of the standardised ratios (NTRK1/Actin) of both NTRK1 bands. As can be seen in 
Figure 14, the results are similar than the ones obtained by normalising phosphorylated Erk 
and Akt to the endogenous Erk and Akt, suggesting total receptor levels do not substantially 
influence the activation or the kinetics of the signalling pathways.  
 
 
5.1.4   Cellular localisation of NTRK1 
As noted above, Western blot analysis showed that mutant p.N365K predominantly migrated 
as a ~110 kDa protein band, suggesting an improper processing or trafficking to the PM. 
Thus, the next step was to address the subcellular localisation of the wild-type and mutant 
NTRK1 proteins. HeLa cells were co-transfected with a fusion protein of K-Ras (HVR)-
mCherry and the different NTRK1 receptors and further analysed by confocal microscopy. K-
Ras was used as a membrane marker as it is activated by cell surface receptors and localises 
predominantly to the PM. As can be seen in Figure 15, wtNTRK1 and mutants p.I505N and 
p.Q633R show membrane localisation, while mutant p.N365K is not colocalizing with K-Ras 
(HVR)-mCherry and shows a perinuclear reticular pattern, indicating that this mutant is 
retained either in the Golgi apparatus or the endoplasmic reticulum (ER). 
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5.1.5   Neurite outgrowth 
Activation of the Akt and Erk signalling pathways triggered by NTRK1 upon NGF 
stimulation results in morphological and biochemical differentiation of wild-type PC12 cells 
into a neuronal phenotype (160). Accordingly, the ability of the NTRK1 mutants to induce 
these changes was addressed. For this purpose, Ntrk1-KO PC12 cells were transiently 
transfected with the wtNTRK1, the three mutant constructs and GFP, and treated with NGF 
(100 ng/ml) for three days.  
 
As expected, 25 % of Ntrk1-KO PC12 cells transfected with wtNTRK1 differentiated into a 
neuronal phenotype (Figure 16). However, cells transfected with mutants p.I505N and 
p.Q633R presented a strong reduction in the percentage of differentiated cells. The p.N365K 
mutation led to a significant decline in the proportion of differentiated cells to 9 %. In the 
GFP control, only 2% of transfected cells could be classified as having neurites two times 
longer than the cell body, which represents the percentage of spontaneously differentiated 
cells.  
 
Altogether, the biochemical and biological data indicate a loss of function for all three 
NTRK1 mutants.  
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5.2   Generation of double-knockout mice by simultaneous targeting of the genetically 
linked genes Scn10a and Scn11a using the CRISPR/Cas9 system. 
 
The alpha-subunits of the voltage-gated sodium channels NaV1.8 and NaV1.9 are encoded by 
Scn10a and Scn11a, respectively. Both ion channels are highly expressed in pain-sensing 
(nociceptive) neurones and have been involved in pain-related disorders in humans (51, 52, 
54, 57, 60). Both channels are essential for the excitability of peripheral nociceptors. 
However, the single knockout of each gene only results in minor pain-related phenotypes. 
Thus, the generation of a Scn10a/Scn11a
-/- 
double-knockout (DKO) mouse will be a valuable 
model to study the combined effect of both ion channels on pain-sensing pathways. Second, 
DKO DRG neurones are an ideal tool to investigate heterologously expressed NaV1.8 and 
NaV1.9 mutants and their role in human diseases. 
 
Both Scn10a and Scn11a are located in close proximity on chromosome 9 and arose from 
gene duplication of an ancestral gene (161). Due to the short physical distance between them, 
these genes are genetically linked and inherited together, precluding that DKO animals can be 
generated by breeding of single knockout mice (Scn10a 
-/-
 x Scn11a 
-/-
). Therefore, the 
generation of the DKO mice was envisioned using the CRISPR-Cas system, targeting both 
genes simultaneously. 
 
5.2.1   Generation of a double-knockout Scn10a and Scn11a mouse model via CRISPR 
genome editing: targeting strategy design.  
The CRISPR-associated protein 9 (Cas9) nuclease generates an RNA-guided blunt double-
strand-brake (DSB) at a targeted genomic sequence immediately upstream of the protospacer-
adjacent-motif (PAM). Consequently, the non-homologous end-joining (NHEJ) repair 
pathway is activated. This error-prone repair mechanism frequently results in deletions and 
insertions (indels), inversions, duplications, as well as base substitutions near the cleavage site 
that might disrupt the gene-coding sequence (73, 125). Simultaneous targeting two genes 
residing next to each other adds another layer of complexity regarding the possible 
rearrangements produced by the repair mechanisms of cells, including inversions and fusions 
between exons. Moreover, editing can occur on alleles of the two different homologous 
chromosomes (in trans) or the same chromosome (in cis). Only the latter event is useful to 
produce a Scn10a/Scn11a double-knockout line. Accordingly, the targeting and genotyping 
strategy had to take into account the different outcomes of CRISPR-aided-mutagenesis. 
                                                                                                                                                         Results 
65 
 
Consequently, the selected approach involved targeting independent exons in each gene to 
avoid novel transcripts from gene fusion. Hence, it was expected that at least one cut would 
occur in the same chromosome resulting in a frameshift mutation in both consecutive genes. 
Each gene was screened for potential single guide RNAs (sgRNAs) that minimised off-target 
cleavage in order to reduce detrimental effects of mutations and chromosomal rearrangements 
using the online design tool from Benchling (www.benchling.com). Two 20-nt-sgRNAs were 
designed per gene. For Scn10a, sgRNAs targeting exon 6 (Ex6) and exon 11 (Ex11) were 
selected, while sgRNAs targeting exon 9 (Ex9) and exon 10 (Ex10) were chosen for Scn11a 
(Figure 17). The cleavage sites in exon 6 and 11 are separated by 6650 bp, while in exon 9 
and 10 they are separated by 1234 bp. A precise deletion of the region between both cuts in 
each respective gene would lead to a frameshift mutation. 
 
 
 
′ ′
′
  
5.2.2   Construction of CRISPR-Cas9 plasmids.  
The four 20-nt sgRNA sequences with or without an extra 5’-G were directionally cloned into 
the pX330 vector, which co-expresses hSpCas9 and an sgRNA cloning site under the chicken 
beta-actin hybrid (CBh) and human U6 promoters, respectively (147) (Figure 18A). 
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5.2.3   Generation of Scn10a/Scn11a double-knockout mice by pronuclear injection of 
CRISPR-Cas9 plasmids.  
Next, the feasibility of using CRISPR-Cas9 plasmids to generate DKO mice was addressed. 
The four pX330 plasmids were simultaneously microinjected into pronuclei of fertilised eggs 
at a final concentration of 5 ng/µl or 10 ng/µl prior to transplantation into the oviducts of 
pseudopregnant female mice. A total of approximately 100 zygotes collected from C57/BL6 
mice were used for each injection. To reduce the risk of DNA integration into the host 
genome, plasmid DNA was injected in its circular form as illustrated in Figure 18A. One 
foster mother per injection gave rise to six pups for the first injection (5 ng/µl) and five for the 
second one (10 ng/µl). Tail biopsies were taken at postnatal day 10 for genomic DNA 
extraction. As an initial genotyping screening, PCRs for each exon were performed (PCR A, 
B, C, D; Figure 18B) to detect mutations induced by NHEJ using primer pairs listed in Table 
10, subjected to 2% agarose gel electrophoresis (Figure 18C, 14D), and further sequenced. 
Surprisingly, none of the pups had modified alleles in any of the four exons targeted (Figure 
18D). Hence, this approach was discontinued, and alternative strategies were considered (see 
below).
 
 
 
 
 
 
 
                                                                                                                                                         Results 
67 
 
 
′
′
 
                                                                                                                                                         Results 
68 
 
5.2.4   Generation of knockout mice by cytoplasmic injection of SpCas9 mRNA and 
sgRNA. 
As the use of plasmid DNA for the generation of the DKO mice was unsuccessful, a second 
round of injections was performed using mRNA. For this purpose, the pX330 plasmids were 
used as template for the generation of four sgRNAs targeting Scn10a and Scn11a by the T7 
RNA polymerase/promoter in vitro transcription system. To test whether Scn10a/Scn11a
-/- 
DKO mice could be produced, these validated sgRNAs (Figure S6) were microinjected 
together with SpCas9 mRNA into the cytoplasm of ~100 one-cell mouse embryos at 6.25 
ng/µl for each sgRNA and 25 ng/µl for SpCas9 mRNA as illustrated in Figure 19A. 
Pseudopregnant female mice were implanted with the resulting viable embryos, and two of 
them gave birth to a total of 16 pups. Genomic DNA was prepared from mouse tails, and 
genotyping PCRs were performed for each exon as described in the previous section followed 
by 2 % agarose gel electrophoresis. As can be seen in Figure 19A, using this approach several 
mice were genetically modified as assessed by the presence of bands of different size. 
Interestingly, a single band of the same size was detected for Scn10a-Ex6 in all pups except 
for #11 and #14 (12.5%), which seemed to miss the entire exon as judged by the lack of PCR 
amplification. A missing amplicon was also observed for Scn11a-Ex9 in pups #8 (6.25%), 
whereas in pups #13 and #14 Scn11a-Ex10 was missing (12.5%). Also, more than two bands 
were observed in animal #4 (Scn11a-Ex10), indicating that this mouse was heterozygous. 
Moreover, pups number #7, #8 presented a faster-migrating PCR-product for Scn11a-Ex10, 
suggesting a homozygous deletion. Furthermore, PCR amplification with primers spanning a 
larger region around the cleavage site confirmed a larger deletion in pups #7 (Scn10a-Ex6) 
and #4 (Scn11a-Ex10) (Figure S7).  
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To analyse the F0 mice in more detail, polyacrylamide gel electrophoresis (PAGE)-based 
genotyping was performed, as it enables the identification of heterozygous and homozygous 
mutations with higher sensitivity than separation in agarose gels (137). Thus, the genomic 
regions spanning the targeted sites were PCR amplified and subjected to 5% PAGE. In case of 
heterozygous indel mutations, DNA heteroduplexes with a characteristic mobility pattern will 
form enabling the assessment of number and type of mutation. In wild-type control mice, 
PCR amplification yielded one single band of the respective size for each exon (Figure 20A). 
However, multiple heteroduplexes were detected in 9 of 16 mutant mice (56.25%), which was 
significantly higher than aberrant bands identified by 2% agarose gel electrophoresis 
(18.75%). Several animals displayed a single pair of heteroduplex bands, indicating one 
dominant type of indel mutation. For instance, animals #4, #13 and #15 revealed 
heterozygosity for Scn10a-Ex11 (18.75%). In addition, animals #4, #7, #9, #11, #12, #13, #14 
and #15 were heterozygous for Scn11a-Ex9 (50%), while animals #4, #6 and #15 bear 
heterozygous mutations in Scn11a-Ex10 (18.75%). Remarkably, pups #4 and #15 were 
heterozygous for the three exons (12.5%) and exhibited multiple pairs of heteroduplex bands, 
suggesting mosaicism.  
 
Using this method one can also identify homozygously targeted mice with small indels. For 
this purpose, PCR products from F0 mutant mice were mixed with products from wild-type 
mice followed by brief denaturation and annealing, and once more subjected to 5% PAGE. As 
can be observed in Figure 20B, mouse #6 (Scn11a-Ex9), as well as mice #7 and #12 (Scn11a-
Ex10), exhibited migration patterns indicative for homozygous indels.  
 
It is important to notice that an absence of a heteroduplex does not exclude that gene editing 
has occurred. Thus, sequencing was done to confirm results as well as to identify mice with 
nonsense or frameshift mutations. Additionally, PCR products were subcloned into TOPO 
vector to allow allele-specific analysis. Several targeted mutations were found in the F0 mice, 
including small deletions, small insertions, and nucleotide substitutions. 
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5.2.4.1   Precise large deletions can be induced by the CRISPR/Cas9 system  
The use of more than one sgRNA might lead to larger deletions between both sgRNA target 
sites. To test this possibility, a combination of primers from PCRs A, B, C and D was used to 
amplify deleted regions between cleavage sites as shown in Figure 21A. In Scn11a, the 
CRISPR targeting sites are separated by only 1.2 kb. The forward primer of PCR A and the 
reverse primer of PCR B were combined (PCR E, Figure 21A) to amplify the anticipated 
deleted region of ~0.5 kb. As shown in Figure 21B, several mice presented a band of smaller 
size, suggesting that different rearrangements occurred in these animals. Sequencing 
confirmed that four mice (#5, #6 and #14, #15) contained an allele with a precise exon 
junction leading to a premature stop codon (25%), as illustrated in Figure 21C. On the 
contrary, pups #4 and #9 contained a large deletion following the cleavage site of exon 9, but 
exon 10 was indeed present. More precisely, animal #4 was missing a region of 1050 bp 
together with a ∆1 bp in exon 10, while pup #9 had a ∆1078 bp (see Figure 22). Pup #13 
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presented an allele with an extra nucleotide in the junction. While the possible outcome of the 
rearrangements in the first two pups (#4, #9) is hard to predict as half of exon 9 is missing, the 
modification in the latter (#13) is detrimental as it leads to a premature stop codon. 
Furthermore, several mice that were not further analysed presented a faint band at the 
expected size, suggesting they might carry a similar deletion.  
 
The two targeting sites located in Scn10a are separated by 6.65 kb. Deletion of this region 
would lead to a substantially smaller PCR product of approximately 0.5 kb when combining 
the forward primer of PCR C and the reverse primer of PCR D (PCR F, Figure 21A). 
Interestingly, 2% agarose gel electrophoresis of the resulting PCR products revealed that 2 out 
of 16 mice (12.5%) carried the desired deletion as can be seen in Figure 21B. Sequencing of 
the PCR products confirmed that both mice exhibited a precise joining of predicted cleavage 
sites (Figure 21D), leading to a premature stop codon in Scn10a. 
 
To test whether an even larger deletion was induced, a PCR using the forward primer of PCR 
A and the reverse primer of PCR D was performed. Deletion of the 141 kb region between the 
most distant cleavage sites would produce a band of ~470 bp (PCR G, Figure 21A). 
Strikingly, pups #7 and #14 presented this astonishingly large deletion as can be seen in 
Figure 21B. Sequencing confirmed that both mice contained an allele with a precise exon 
junction leading to a premature stop codon (12.5 %), as shown in Figure 21E. 
 
5.2.4.2   Establishing a detailed genotype for F0 mice.  
Based on the previous findings, a genotype for each of the 16 mice was determined. A 
comprehensive description of the mutations found in the F0 mice is depicted in Figure 22, and 
the results are summarised in Table 13.  
 
Interestingly, some mice carried homozygous mutations in both alleles. For instance, mouse # 
11 had a homozygous ∆1 bp in both genes. Although mosaicism cannot be excluded, this 
mouse seems to be a homozygous DKO. This observation strongly suggests that a combined 
Scn10a and Scn11a-deficiency is not lethal. 
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5.2.4.3   Founder selection and analysis of germline transmission from F0 mice to their 
progeny 
Given the high number of detected mosaic mice, it was important to identify germline alleles 
that could be transmitted to the offspring leading to a DKO line. Therefore, two mice were 
chosen for further breedings, F0#11 and F0#14, as they contained the most promising alleles 
for gene disruption. The first animal contained a heterozygous deletion of the entire Scn10a-
Ex6, a homozygous T>A c.1392 mutation along with a ∆1 bp in Scn10a-Ex11, a 
heterozygous ∆10 bp together with a substitution (CA>AG) in Scn11a-Ex9, and a 
homozygous ∆1 bp in Scn11a-Ex10. The second animal was mosaic and contained several 
null mutations including exon junctions between Scn11a-Ex9 and Ex10 as well as Scn11a-
Ex9 joined with Scn10a-Ex11.  
 
Both animals were mated with two C57BL/6J female mice, and the progeny was analysed. As 
depicted in Figure 23, F0#14 transmitted several mutations, including 2, 3, or 9 bp deletions, 
and a 14 bp insertion plus a G>T substitution (Figure S8). However, none of the allele 
combinations was suitable for the generation of a DKO line.  
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On the other hand, F0#11 transmitted two different allele combinations. As shown in Figure 
23, half of the offspring from this mouse contained the expected ∆1 bp in Scn11a-Ex10 along 
with the ∆10 bp plus substitution (CA>AG) in Scn11a-Ex9 that together caused a premature 
stop codon in Scn11a. However, these animals had no mutations in Scn10a. The other half of 
the littermates contained a T>A substitution along with a ∆1 bp in Scn10a-Ex11 plus a novel 
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∆4 bp in Scn11a-Ex9 (see Figure S8). Interestingly, in this case, mutations causing a 
premature stop codon in both genes occurred in cis. Taken together, these results suggest that 
a detailed analysis of the F1 generation is essential to identify which mice carry the desired 
genome-engineered alleles.  
5.2.4.4   Off-target analysis in CRISPR/Cas-mediated mutants.  
The CRISPR-Cas9 system can lead to undesired off-target (OT) cleavage and subsequent 
unwanted mutations as the SpCas9 enzyme can tolerate certain mismatches between the 
sgRNA and the target DNA as well as use an alternative PAM sequence, 5’-NAG (138). In 
the present study, OT sequences were computationally identified and ranked using the online 
design tool from Benchling (www.benchling.com) (Table S3, S4, S5, S6), tolerating up to 
four mismatches in the target gRNA sequence (138). For each sgRNA, primers for the top 
five OT sequences and OT coding regions were designed (Table 11). The regions containing 
the potential OT sites were amplified and further sequenced to determine if any mutations or 
changes occurred. Only the founder chimaera (F0#11) and two F1 founder animals (F1#5, 
F1#6) were analysed. A total of 23 OT sites were examined (five OT sites for Scn10a-Ex6 and 
six for each Scn10a-Ex11, Scn11a-Ex9/10). Although other potential OT effects cannot be 
excluded, no indel mutation was observed in the analysed OT regions in any of the mutant 
mice (Figure S9), suggesting a high specificity of the CRISPR-Cas9 system.  
 
5.3   Knockout validation and phenotype assessment. 
Two F1 mice containing the correct allele combination were further mated to generate a 
Scn10a/ Scn11a 
-/-
 mouse line. Scn10a/Scn11a DKO mice were born at the expected 
Mendelian ratio from heterozygous breedings, indistinguishable from Scn10a/Scn11a wild-
type mice. In addition, they did not show an increased mortality compared to their wild-type 
littermates. Sequencing of Scn10a/Scn11a 
-/- 
mice confirmed the correct transmission of the 
desired alleles (Figure 24A). Moreover, homozygous Scn10a/Scn11a DKO mice were fertile 
and did not show apparent abnormalities or deficits until 24 months of age. 
 
Importantly, Scn10a and Scn11a mRNA expression was not detected by qPCR in the dorsal 
root ganglia of these mice (using primers targeting intact exons - 4/5 for Scn10a, 12/13 for 
Scn11a- listed in Table 12) as shown in Figure 24C. Gapdh expression served as 
housekeeping gene for all cDNA samples.  
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Additionally, the double-knockout was verified by electrophysiological studies conducted by 
Dr. Enrico Leipold (Department of Biophysics, Jena). Nociceptive sensory neurones express a 
variety of sodium channel isoforms, including the tetrodotoxin resistant (TTX-R) NaV1.8 and 
NaV1.9 (33, 34) and TTX-sensitive sodium channels (162–165), as well as voltage-dependent 
calcium channels (166). Figure 24D illustrates the effect of TTX on total voltage-gated 
sodium current elicited by step depolarizations in small diameter dorsal root ganglion (DRG) 
neurones isolated from wild-type mice. As expected, upon application of 1 µM tetrodotoxin 
(TTX) the only sodium currents recorded are carried by the TTX-R sodium channels NaV1.8 
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and NaV1.9. On the contrary, Scn10a/Scn11a
-/- 
small diameter DRG neurones show complete 
inhibition of sodium currents upon TTX application, demonstrating the absence of 
endogenous NaV1.8 and NaV1.9, thus verifying the successful knockout of Scn10a and 
Scn11a. Together, these results show that Scn10a/Scn11a
-/- 
mice were successfully generated 
with the CRISPR-Cas9 system by cytoplasmic injection of Cas9 mRNA and sgRNAs. 
5.4   Scn10a/Scn11a
-/-
 DRGs enable functional analysis of human NaV1.8 and NaV1.9.  
To investigate whether the activity of the TTX-R channels can be rescued in the DKO-DRG 
neurones, whole-cell current recordings were performed from isolated DRG neurones 
transiently transfected with wild-type (wt) cDNA constructs encoding human NaV1.8 and 
NaV1.9. As shown in Figure 25B and Figure S10, successful transfection gave rise to 
functional expression of human NaV1.8 and NaV1.9. 
 
ND7/23 cells (hybrids of neuroblastoma and dorsal root ganglia cells) were also transfected 
with wtNaV1.9 as a positive control, as they were previously shown to enable the expression 
of functional human NaV1.9 channels (57, 167). As in these cells all endogenous sodium 
channels can be effectively inhibited with TTX, they represent a useful tool for the functional 
analysis of NaV1.9. As shown in Figure 25A, the characteristic slowly activating and 
inactivating NaV1.9-specific currents are evoked by step depolarizations in transfected cells. 
However, the achievable NaV1.9-specific current amplitudes obtained were significantly low, 
ultimately making the analysis time-consuming. On the contrary, in DKO-DRG neurones 
transfected with wtNaV1.9 considerably larger current amplitudes were observed, allowing a 
more precise analysis of the channel kinetics. Moreover, thanks to the absence of TTX-R 
NaV1.8 channels in the DKO-DRGs, which would interfere with recordings of  NaV1.9-
specific currents (57), the new DKO-model provides a powerful, straightforward expression 
system for the analysis of NaV1.9 channels at high resolution.   
 
Therefore, to prove that this mouse model can be used as an expression system to study 
mutations in TTX-R channels, in particular in NaV1.9, isolated DRG neurones from DKO 
mice were transiently transfected with NaV1.9-L811P variant (c.2432T>C, p.Leu811Pro), 
which leads to pain insensitivity in humans. Transfection of ND7/23 with this variant showed 
a left-shift in the resting membrane potential, indicating that mutant channels are active under 
resting conditions, as well as a slower inactivation kinetics (57). We were able to reproduce 
these results using the DKO-DRG neurones (Figure 25B, C), suggesting these cells are a 
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valuable tool for the characterization of TTX-R channel variants involved in human disease as 
well as for pharmacological studies.  
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6. Discussion 
 
One of the breakthroughs in the past decades of molecular biology has been the sequencing of 
the Human Genome, an international research effort that has provided us with the complete 
map of all genes in our species. Thanks to this innovation, nowadays we can comprehensively 
diagnose human diseases at gene level. However, only a few of the estimated 20.000 protein-
coding genes in the human genome have a well-defined function (168). Hence, understanding 
gene function and the consequences of genetic variations remain an important goal and a 
major challenge. 
 
Comparative genomics has revealed high sequence homology between large parts of mouse 
and human genomes (169). Therefore, mice have proven a well-suited model for in vivo 
functional genomics in human research. A straightforward method to elucidate the function of 
a gene is to generate a complete knockout and characterise the phenotype. Up to now, gene 
knockouts have proven suitable for elucidating the role of genes involved in a wide variety of 
biological pathways, including human behaviour, physiology, metabolism, development and 
cancer (170). In addition, gene knockout organisms are excellent models for studying the 
underlying mechanisms of human genetic diseases and provide an invaluable tool for the 
development of new therapeutic approaches (171).  
 
Over the past two decades, this method has been used to unveil the role of more than 5,000 
mammalian genes (172). However, when using classical homologous recombination 
approaches (see Figure 26A), targeting efficiency is usually low and requires screening of 
several hundreds of embryonic stem (ES) cell clones. Besides, gene targeting is dependent on 
both the length and the extent of homology between the donor vector and the target locus 
(173, 174), thus requiring the generation of huge vectors to achieve a higher recombination 
efficiency. Hence, this approach remains arduous, expensive, time-consuming, and is not well 
suited for targeting different loci at the same time. 
 
An alternative method to perform targeted genome-editing is the use of zinc-finger nucleases 
(ZFNs) and transcription activator-like effector nucleases (TALENs). These enzymes are 
artificially produced by the fusion of several DNA-binding modules that recognise 3 (ZFNs) 
or 1 nt (TALENs) in the target DNA sequence fused with a FokI endonuclease. The resulting 
enzymes recognise specific genomic locations via protein-DNA interactions (68). The FokI 
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domain is responsible for the generation of a double strand break (DSB) in the target site, 
which is subsequently repaired via the error-prone non-homologous end joining (NHEJ) 
pathway, often leading to small indels. Specific mutations can also be achieved by co-
introduction of a homologous single or double-stranded DNA via homology-dependent repair 
(HDR) or high-fidelity homologous recombination (HFHR) (175). Following these principles, 
numerous research groups have recently efficiently generated gene-targeted mice and rats by 
injecting mRNA coding ZFNs or TALENs directly into the zygote (176, 177). Nevertheless, 
the design and preparation of these enzymes have proven labour intensive and complex, 
ultimately halting the spread and use of this technique. 
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The recently developed CRISPR-Cas9 genome editing technology has certainly 
revolutionised the field of genetics, not only in organisms in which gene manipulation was 
not previously possible but also in the laboratory mouse. Similarly to ZFNs/TALENs, the 
Cas9 enzymes are endonucleases that can be programmed to cause a site-specific DSB and 
exploit the cellular repair machinery to produce mutations (Figure 26B). However, in contrast 
to ES gene-targeting and ZFNs/TALENs nucleases, the CRISPR-Cas9 system is highly 
efficient, less time consuming, straightforward, and exhibits a remarkable versatility for 
complex editing and simultaneous targeting of loci, as proven by the results presented in this 
thesis. In addition, the CRISPR-Cas9 system provides a simple method to disrupt genes in all 
types of cell lines.  
 
6.1   Generation of Ntrk1-KO PC12 cells 
In this study, genome-edited rat PC12 cells were successfully generated using the NmeCas9 
by targeting the enzyme to exon 5 of the Ntrk1 gene. However, the targeting efficiency 
obtained (20%) was significantly lower than previously reported (131, 132). This might be 
due to the nature of PC12 cells. These cells are not easy to handle and have low division rates. 
From the 200 starting single cell clones, only 30 proliferated into colonies. From the latter, 
two clones were homozygously targeted, and the indels introduced by NHEJ caused a 
frameshift mutation.  Neither clone expressed Ntrk1, as assessed by qPCR. As expected, these 
clones were not able to differentiate into a neuron-like phenotype or trigger the PI3K or 
MAPK pathways upon NGF treatment. Moreover, the selected gRNA only had two predicted 
off-target sites, as examined by Benchling and COSMID, making off-target analysis 
straightforward. None of these locations contained undesired indel mutations. Compared to 
other reports (73, 132), the results suggest that NmeCas9 has a similar or lower on-target 
cleavage activity than SpCas9 but a reduced off-target effect on a genomic level (132). Thus, 
although only very limited studies have been made for the use of NmeCas9 to target 
endogenous loci in mammalian cells (131,132), this enzyme may represent an excellent 
choice for genome engineering applications. 
 
6.2   Functional analysis of novel NTRK1 missense mutations 
In this thesis, three novel missense mutations in the NTRK1 gene found in patients diagnosed 
with HSAN-IV are reported. The generated Ntrk1-KO PC12 cells proved to be a valuable tool 
for studying the underlying disease mechanisms of these NTRK1 mutations in a 
physiologically relevant cellular context. Mutation p.N365K is located in the extracellular 
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portion of the receptor. Specifically, in the second immunoglobulin-like domain of the 
protein, which is partially responsible for NGF binding (20). Based on the location of the 
mutation, one could anticipate that it could prevent NGF binding. However, western blot 
analysis and immunofluorescence revealed that this variant is not properly transported to the 
plasma membrane and is retained in the endoplasmic reticulum (ER), most probably due to 
protein misfolding (see Figure 27). Moreover, this mutation highly reduced the differentiation 
capacity of transfected Ntrk1-KO PC12 cells and did not activate the MAPK or Akt signalling 
pathways. Interestingly, two recently reported mutations responsible for an HSAN-IV 
phenotype, p.L93P and p.L213P, located in the leucine-rich and first immunoglobulin domain 
respectively, likewise produce the 110 kDa NTRK1 isoform only and are retained in the ER 
compartment, suggesting a common pathogenic mechanism responsible for the disease (178–
180). Protein misfolding not only affects protein function but also leads to aggregation and 
toxicity. Accumulation of misfolded proteins in the ER, which contributes directly to ER-
stress-induced neuronal apoptosis, is a common cause of developmental and progressive 
neurodegenerative disorders (181). Misfolded proteins that are induced by gene mutations 
have been identified in other neurodegenerative diseases, such as Parkinson’s and 
Alzheimer’s disease, in which accumulation of misfolded proteins induces neuronal loss and 
cognitive deficits (181), which is consistent with the mental retardation often seen in HSAN-
IV patients (180). 
 
Neurotrophin signalling is a complex, highly regulated process. A series of studies provided 
evidence that supports a model in which neurotrophin-NTRK receptor complexes are 
internalised in distal axons into an endocytic signalling platform termed the ‘signalling 
endosome’ (182). Sustained MAPK signalling needed for neuronal differentiation seems to be 
maintained exclusively from endosomal locations through activation of Rap1, a member of 
the GTPase family, while transient activation of Ras-dependent signalling along with Akt 
phosphorylation occurs at the cell surface to promote neuronal survival (159, 160). Mutation 
p.I505N localises to the very end of the juxtamembrane region of the NTRK1 receptor, while 
p.Q633R localises to the middle of the tyrosine kinase domain. None of these mutations affect 
residues that may interfere with receptor autophosphorylation or protein function. However, 
these mutants were unable to induce differentiation of Ntrk1-KO PC12 cells into a neuronal-
like phenotype after three days of NGF treatment, suggesting that they are not rare 
polymorphisms, but disease-causing missense mutations. When the cellular localisation was 
addressed, both mutants partly localised to the plasma membrane, suggesting there is no 
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defective glycosylation and consequent membrane trafficking defect. Moreover, Western blot 
analysis confirmed the presence of the fully glycosylated mature isoform of ~140 kDa in both 
mutants. Additionally, Akt phosphorylation kinetics induced by NGF were not altered in 
transfected cells. However, when the Erk pathway was addressed, a significant difference 
between these mutant receptors was observed after 30 min of NGF stimulation. In cells 
transfected with wtNTRK1, Erk activation has its peak at 5 min post-NGF stimulation and 
remains almost constant for 30 min. However, in cells transfected with mutants p.I505N and 
p.Q633R, Erk activation can be observed after 5 and 10 min of NGF treatment suggesting 
proper Ras activation, but it is not detected after 30 min, probably due to defective Rap1 
activation. Thus, based on these results, it can be speculated that these mutants have deficient 
internalisation into early endosomes or fail to interact with adaptor proteins needed for Rap1 
activation (See Figure 27).  
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6.3   Generation of Scn10a and Scn11a double-knockout mice 
 
6.3.1   Pronuclear injection of SpCas9/sgRNA expressing vectors vs. mRNA injection of 
SpCas9 and sgRNA.  
One method that can be used to generate genetically modified mice by the CRISPR-Cas9 
system is the pronuclear injection of the pX330 vector containing the single guide RNA 
(sgRNA) and the Streptococcus pyogenes humanised Cas9 (hSpCas9) endonuclease (73).  
Upon injection of the plasmid into one of the pronuclei of fertilised oocytes, SpCas9 is guided 
to the target site and generates a DSB, subsequently producing indels that will most likely 
cause a frameshift in the reading frame. Despite several groups successfully generated KO 
mice by this approach (183–185), including us (data not shown), upon injection of four 
pX330 vectors targeting the different exons of Scn10a and Scn11a into C57BL/6N zygotes, 
unfortunately, no mutations were detected in the desired loci. Another possible method is the 
cytoplasmic injection of SpCas9 mRNA and in vitro transcribed sgRNAs. When these 
components were injected into zygotes, we observed mutation rates up to 75%, including 
several mice containing mutations in all the alleles targeted (18.7%).  
 
Although DNA injection is less expensive, time-efficient, and evades the preparation of RNA, 
which requires careful handling and storage, as reported by other groups (183–185) and based 
on my own experience, the targeting efficiency is significantly lower. This can be attributed to 
the toxicity of DNA and expression efficiency of the CRISPR/Cas9 components upon 
injection. In fact, as plasmids require transcription, pronuclear injection is needed, but 
identifying the tolerable plasmid-DNA-concentration for injection into embryos was a 
complicated task. Injection into pronuclei was more damaging to zygotes than injection of the 
same volume or concentration of editing reagents into the cytoplasm. Also, injections with 
higher DNA concentrations than reported in the results section resulted in several failed 
attempts to obtain viable embryos and pups (data not shown). Despite numerous attempts over 
an extended period of time, only eleven pups were born from DNA injections compared to the 
amount of injected embryos (~5%), and none was genetically modified. Thus, these results 
suggest that injection of pX330 plasmids into the pronucleus of zygotes may not be the 
preferred method for the generation of genetically modified mouse models.  
 
In contrast, the generation of mice carrying germline mutated alleles of interest was 
remarkably successful via mRNA injection. Cytoplasmic injection of a mixture containing 
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sgRNAs and SpCas9 mRNA might facilitate protein translation. Moreover, it proved to be 
less toxic for the embryos, yielded three-fold more live born pups compared to the number of 
injected embryos (~15%) than DNA injection, and the overall editing efficiency was 
significantly higher. Based on these results (and data not shown) injecting SpCas9 mRNA at 
25 ng/µl and sgRNA at a concentration between 25 to 6.25 ng/µl into the cytoplasm yields 
good survival of embryos and efficient editing by NHEJ. Another advantage of cytoplasmic 
injection is that visible pronuclei are not necessary for fertilised eggs to be injected, thus 
enabling injection in a broader range of oocytes, ultimately reducing total superovulated mice 
numbers. The results suggest that ten donor mice (~10 embryos/mice) might be sufficient for 
the generation of genetically modified mice by cytoplasmic injection of editing reagents.  
 
All methods needed to be established, including plasmid cloning, PCR amplification of DNA 
templates, in vitro transcription (IVT), guide validation, and, in particular, microinjection. 
Once this was achieved, the whole process became straightforward and highly efficient, 
taking approximately three weeks. Indeed, in less than seven months the Scn10a/Scn11a
-/-
 (F1) 
line was established (see Figure 28). Moreover, backcrossing was not necessary as C57BL/6N 
zygotes were used, thus generating mice with a pure genetic background. Overall, the results 
support the fact that mRNA injection of SpCas9 and sgRNA is a rapid, simple and 
reproducible method for the one-step generation of double-knockout mice. 
 
 
 
6.3.2   The CRISPR-cas system can be used to target neighbouring genes 
Usually, the generation of mice carrying mutations in several genes requires time-consuming 
intercrossing of single-mutant mice. However, as the Scn10a and Scn11a genes are in close 
physical chromosomal distance (genetically) linked, i.e. they are inherited together, this 
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procedure is not applicable to generate DKO mice. On the other hand, the distance between 
Scn10a and Scn11a excludes one-step homologous recombination strategies. Instead, a 
sequential approach may be considered, targeting one gene first, and subsequently, use this 
line as donor for the disruption of the second gene. Still, this process is extremely labour 
intensive, necessitating multiple consecutive cloning steps and subsequent breeding steps 
(147). Hence, the CRISPR-Cas9 system proves to be highly advantageous as it provides a 
methodology for efficient simultaneous one-step targeted mutagenesis of genomic loci in 
mice.  
6.3.3   Analysing the outcome of CRISPR genome editing in mice.  
Though several reports describe the generation of mouse models via CRISPR-aided 
mutagenesis, only a few mention the diverse modifications that may occur and their 
complexity in detail (161, 186). Cas9-generated DSBs directed at multiple loci and within 
various parts of the same gene led to complex allelic outcomes, and each founder mouse 
carried a different combination of mutated alleles, overlaid with the issue of mosaicism at 
each locus. 
 
One unexpected result was the robustness and the high number of mosaic animals (43.75 %) 
carrying three or more modified alleles obtained by microinjection of RNA-CRISPR-reagents 
into zygotes, which became an outstanding challenge. Cas9 mRNA translation is most likely 
delayed until after the first cell division as transcription and translation are suppressed in 
mouse zygotes (187). Moreover, editing may happen after several cell divisions, due to the 
persistence of Cas9/sgRNA complexes, further contributing to genetic mosaicism.  
  
Therefore, the complexity of allelic variations generated by the microinjection of 
CRISPR/Cas9 reagents into embryos requires detailed genotyping analysis. Several 
techniques can be employed to characterise the mutants, including agarose electrophoresis, 
Surveyor® (73) or T7EI assays, PAGE (137), Sanger or next generation sequencing (188), 
and Droplet Digital PCR (189). For the production of Scn10a/Scn11a
-/- 
mice, 2% agarose 
electrophoresis and 5 % PAGE were chosen as initial screening steps. PAGE proved to be an 
excellent, simple, and efficient screening methodology, enabling the identification of 
homozygously and heterozygously targeted mice. The results suggest that for future 
applications, PAGE can be sufficient as an initial screening. However, as described by Zhu et 
al., a higher gel percentage is recommended to increase the sensitivity of the results (137). 
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Moreover, PAGE gels are cost-saving and were easier to perform than the Surveyor® or T7EI 
assays (data not shown).  
 
However, none of these assays can reveal the exact nature of the mutations. Sanger  
sequencing was essential to confirm the actual mutation, and this information was used to 
assess the potential impact on encoded protein and identify the best founder animal to 
generate the double-knockout line. Still, one drawback of this method is that direct 
sequencing of amplicons from founder mice in almost all cases resulted in overlapping and 
asynchronous chromatograms due to the presence of two or more different alleles. To 
overcome this problem, the PCR products were cloned into plasmids, followed by Sanger 
sequencing of a sufficient number of independent clones (usually 10) to identify all alleles in 
the sixteen CRISPR-derived founder animals. This entire process was time-consuming, as not 
all allelic variants were revealed by a single PCR, especially in mosaics. Indeed, as for some 
animals no amplicon was detected for a certain PCR, suggesting exon deletion, a second PCR 
spanning a larger region from the cut site was needed to reveal the exact mutation. Moreover, 
several mice contained exon junctions between the target sites, which also required 
subcloning and further sequencing. One alternative to overcome this problem, but costly, is to 
use next-generation-sequencing of PCR-amplified target loci from founder mice, which also 
enables simultaneous analysis of potential off-target sites. Thus, Sanger sequencing remains 
the best alternative for small labs to analyse CRISPR-edited mice.  
 
Regarding targeting efficiency, as previously mentioned, 75% of mice contained mutated 
alleles. Alleles bearing small indels, exon deletions, and fusions between exons were found in 
the F0 mice. In particular, 18.75 % for Scn10-Ex6, 37.5% for Scn10-Ex11, 62.5% for Scn11-
Ex9 and Scn11a-Ex10. Moreover, 43.75% were mutant for both genes, 43.75% contained 
larger deletions within the same gene, and 12.5% contained a 140 kb deletion between both 
genes. Although all sgRNAs had a similar on-target activity (see below), consistent with other 
reports, allele frequency appears to depend on the genomic loci. Moreover, additionally to the 
alleles characterised in the F0, several new alleles appeared in the F1 generation, as they might 
have been underrepresented in the analysed tissue. Thus, even if a correct allele combination 
is found in the F0 generation, the real analysis should be done in the F1 to ensure the allele of 
interest was transmitted. The F1 stage enables the final characterization of each mutant, as the 
results obtained in the F0 generation rely heavily on the tissue from where the DNA sample 
was extracted (see Figure 28).  
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6.3.4.  SpCas9 targeting activity and specificity.   
One of the main concerns of CRISPR-genome editing is targeting specificity. Several factors 
determine the cleavage specificity of the Cas9 endonucleases. Firstly, the presence of the 
PAM sequence at the 3’ end of the gRNA binding site is a requisite for Cas9 cleavage (125). 
Although a Cas9 of a given bacterial species has a preference for a certain PAM sequence, it 
has been demonstrated that other PAMs can also be tolerated. For instance, the SpCas9 has a 
preference for a 5′-NGG PAM sequence (125), but it has been shown it can also use an 
alternative 5′-NAG PAM (138).  
 
Secondly, the guide sequence. The gRNA pairs with the complementary DNA sequence in the 
genome (on target) but also binds to other sequences with imperfect matches (off-targets) 
(138, 190, 191). Hsu et al. demonstrated that SpCas9 cleavage activity relies on the correct 
matching of the 8–12 nucleotides proximal to the PAM, termed seed sequence. However, one 
base pair mismatches, DNA bulges or RNA bulges, as well as few mismatches distal to the 
PAM can be tolerated (138). Additionally, they generated an online tool that predicts potential 
off-target (OT) binding sites in the genome and calculates quality scores for each gRNA (high 
scores reflect higher specificity). In addition, it calculates an OT hit score based on the 
number, position, and distribution of mismatches to predicted OT sequences (scores reflect 
the probability of gRNA binding) (138). Moreover, base composition of the gRNA and the 
surrounding DNA genomic region plays a major role in sgRNA efficiency (138, 139). Doench 
et al. proved that Spcas9 prefers certain nucleotides at a certain position of the gRNA. Based 
on this observation, they elaborated a scoring algorithm to predict which guides have higher 
activity (on target score, higher scores reflect higher activity) (139).   
 
Therefore, when designing a guide sequence for genome targeting, the specificity regarding 
off-target potential as well as the on-target score is crucial. For the generation of the DKO 
mouse, the online design tool from Benchling was used for gRNA selection, as it integrates 
both on-target and off-target scores algorithms. The complete sequence of Scn10a and Scn11a 
was screened for a guide sequence with the least number of off-target sites and the highest on-
target activity (sgScn10a-Ex6: OT-score 91.9,on-target 54.5; sgScn10a-Ex11: OT-score 88.5,  
on-target 77.5; sgScn11a-Ex9: OT-score 90.6, on-target 54.6; sgScn11a-Ex10: OT-score 80.2, 
on-target 64.5). Potential OT cleavage was examined for each gRNA in the F0 and F1 founder 
animals. Consistent with online predictions, Sanger sequencing analysis of 5-6 of the highest-
scoring OT sites revealed no undesired mutations in these animals. The on-target score can be 
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reflected in the higher mutation rates obtained. Thus, based on these results, it is highly 
important to select gRNAs with high off-target and on-target scores to avoid unwanted 
mutations and to maximise enzyme activity, respectively. Moreover, consistent with recent 
reports (147), these results suggest that potential off-target effects may not be a major concern 
for the implementation of the CRISPR-Cas9 system in genome modification in mouse 
zygotes. Nevertheless, whole genome sequencing would be necessary to fully evaluate OT 
effects. 
 
6.3.5   Scn10a/Scn11a -/- DRG neurones as an expression system 
The phenotypic characterization of the double–knockout mice is currently ongoing, and the 
animals will be assessed for alterations in the pain-sensing pathways. Moreover, the generated 
DKO mice are an excellent model to study NaV1.9 function. The voltage-gated sodium 
channel NaV1.9 has recently been implicated in distinct human pain syndromes, including 
patients with congenital analgesia (57–59) and painful neuropathies (60–65). Both conditions 
are characterised by dominant gain-of-function mutations in NaV1.9. However, the functional 
characterization of the different mutations will enhance our knowledge on these pain 
syndromes and will clarify the diverse phenotypic outcomes, which depend on the type of 
missense mutation.  
 
Studying human NaV1.9 is a challenging task due to poor heterologous expression in 
mammalian cells, especially in non-neuronal cells (192). One option to investigate mutations 
in NaV1.9 is the generation of knock-in mouse models. However, in DRG neurones, the 
assessment of the mechanism by which the mutated ion channel is interfering with normal cell 
function is highly compromised by the overlapping expression of NaV1.8 channels (57). Now, 
these limitations can be overcome by using cells from our genetic mouse model. Indeed, 
NaV1.8 and NaV1.9 currents were absent in DRG neurones derived from DKO mice, and 
transfection of human pain-related NaV1.9 mutations was successful.   
 
Interestingly, NaV1.9-specific drugs might be an alternative treatment for pain syndromes. 
However, this will require exact knowledge on the channel properties and 
electrophysiological characteristics of pain-related mutations and our double-knockout mouse 
model has outstanding potential as a tool for this analysis.  
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7. Conclusion and outlook 
Chronic pain affects millions of people worldwide. Inadequate or insufficient treatment of 
these disorders is partially due to a lack of knowledge regarding the underlying molecular 
mechanisms of pain. Therefore, to gain a deep insight into such mechanisms additional 
cellular and animal models are needed.  
 
In the present work, two independent models for in vitro and in vivo study of pain-related 
genes were successfully generated using the CRISPR-Cas system that will enable the 
exploration of pain mechanisms. Compared with traditional genome editing technologies, this 
short RNA-directed Cas9 endonuclease system proved to be simple, easily programmable and 
allowed me to generate genetically-engineered cells and to target multiple sites in the mouse 
genome in one step. In fact, this system has proven to be suitable to generate both germline 
and somatic indels. Thus, the CRISPR-Cas9 system may act as a novel tool in pain research 
for establishing disease models and studying gene function. Furthermore, taking advantage of 
the homology-directed repair pathways, specific guide RNAs targeting mutations in pain-
associated genes may in the future provide an in vivo gene correction therapy and may be a 
new approach for transcriptional activation or repression of pain-related genes in patients with 
chronic pain. 
 
Using the Ntrk1-KO model, we hope to shed light on the mechanism of action of neurotrophin 
signalling. Here, potentially pathogenic mutations in patients with loss of pain perception 
were functionally assessed and further rated as pathogenic. However, until now, the precise 
mechanisms of NTRK1 internalisation and recycling and its role in disease remain unclear. 
Further questions that should be addressed by future work include: what is the role of the 
mutated amino acids (505 and 633) of the NTRK1 protein in internalisation and recycling? 
Which interaction partners might fail to interact with the mutant proteins? Investigation of 
Rap1 activation by these mutants and internalisation assays might be helpful to dissect the 
mechanism, and experiments are currently ongoing.  
 
DRGs from double KO-mice with simultaneous disruption of Nav1.8 and Nav1.9 will be an 
ideal model to study disease-associated mutants in these sodium channels. Behavioural and 
electrophysiological analysis of this mouse model might be useful to clarify the role of these 
sodium channels in pain perception. Moreover, both models might reveal new therapeutic 
targets for pain management and serve as a tool for drug development. 
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II. Plasmid Maps 
 
1. pSimpleII-U6-tracrRNA-U6-BsmBI-NLSNmCas9-HA-NLS(s), Addgene #47868 
 
 
2. pSimpleII-U6-tracrRNA-U6-BsmBI-NLSNmCas9-HA-NLS-CMV-GFP 
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3. pCI-neo-NTRK1 
 
 
4. pCI-neo-NTRK1-myc 
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5. pX330-U6-chimeric_BB-CBh-hSpCas9 (Addgene plasmid #42230) 
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